	    		            		                                                                                                                                          	    		   		   	  	   	    							    	    																																			    																	    	    	                             		       	                                                                                                           	        						    	    																																			    																	    	    	                             		       	                                                                                                       									    	    																																			    																	    	    	                             		       	                                                                                                       									    	    																																			    																	    	    	                             		       	                                                                                                       	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                                                                                                                                                                                                               	        	                                                                                                                                                                                                                                                                                                                                                                                                                                                             <!DOCTYPE html><html><head><script id="f5_cspm">(function(){var f5_cspm={f5_p:'GICNHHLFPHIHNPLCJMFJOKGAPKBHJKHGLLEBCCCPLKOBODNEABMDMAGFECPAMKLPMBMNOEPEDDKKJCCOADKDFHANLELFDFCJKGLGCEJPAABLKJOCILFPDKHPDJJBGHGO',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}return;}}catch(err){return;}setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}f5_cspm.go();}());</script>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - INVEGA- paliperidone tablet, extended release  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "INVEGA- paliperidone tablet, extended release <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>    <script src="/dailymed/scripts/spin.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>            <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.min.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>					</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>																			<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>					</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">INVEGA- paliperidone tablet, extended release <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AINVEGA%2D%20Paliperidone%20Tablet%2C%20Extended%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D7b8e5b26%2Db9e4%2D4704%2D921b%2D3c3c0d159916%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=invega-02.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=invega-02.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" src="image.cfm?type=img&name=invega-02.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=invega-03.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=invega-03.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" src="image.cfm?type=img&name=invega-03.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                    <h4 class="more closed">VIEW MORE</h4>                                        <div class="show-more">                                            <ul>                                                                                                                        <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=invega-04.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="2">                                                <img id="zoom_3" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=invega-04.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" src="image.cfm?type=img&name=invega-04.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=invega-05.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="3">                                                <img id="zoom_4" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=invega-05.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" src="image.cfm?type=img&name=invega-05.jpg&setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                            </ul>                                     </div>                                                                 </div>            								                                                                                                <div class="mod drug-photos">                                <h2><a>View Drug Photos</a></h2>                                                                    <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Codes:</a></strong>                                        <ul>                                        <li>                                            <ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        <li class="img drug-photo">                                                            	<p>50458-0551-01</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/50458-0551-01_NLMIMAGE10_0F1607A0.jpg"                                                                  class="thumbnail"                                                                  title="24&#x20;HR&#x20;paliperidone&#x20;6&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                 data-slideorder="4"                                                                 data-ndccode="50458-0551-01"                                                                 data-standardname="24&#x20;HR&#x20;paliperidone&#x20;6&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                 data-shape="OVAL"                                                                 data-size="11mm"                                                                 data-color="BROWN"                                                                 data-scored="1"                                                                 data-imprint="PAL&#x3b;6"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_5"                                                                         title="24&#x20;HR&#x20;paliperidone&#x20;6&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                         alt="24&#x20;HR&#x20;paliperidone&#x20;6&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0551-01_NLMIMAGE10_0F1607A0.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0551-01_NLMIMAGE10_0F1607A0.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        <li class="img drug-photo">                                                            	<p>50458-0552-01</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/50458-0552-01_NLMIMAGE10_0E160770.jpg"                                                                  class="thumbnail"                                                                  title="24&#x20;HR&#x20;paliperidone&#x20;9&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                 data-slideorder="5"                                                                 data-ndccode="50458-0552-01"                                                                 data-standardname="24&#x20;HR&#x20;paliperidone&#x20;9&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                 data-shape="OVAL"                                                                 data-size="11mm"                                                                 data-color="PINK"                                                                 data-scored="1"                                                                 data-imprint="PAL&#x3b;9"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_6"                                                                         title="24&#x20;HR&#x20;paliperidone&#x20;9&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                         alt="24&#x20;HR&#x20;paliperidone&#x20;9&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0552-01_NLMIMAGE10_0E160770.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0552-01_NLMIMAGE10_0E160770.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                            </ul>                                        </li>                                    </ul>                                	                                        <h4 class="more closed">VIEW MORE</h4>                                            <div class="show-more">                                                <ul>                                                                                	                                            											                                                                                                                                                                                                                                                                                                                                                                    <li>                                                    <ul>                                                                                        	<li class="img drug-photo">                                                    <p>50458-0554-01</p>                                                                                                                                                            <a href="/rximage.nlm.nih.gov/image/images/gallery/original/50458-0554-01_NLMIMAGE10_E415F27F.jpg"                                                      class="thumbnail"                                                      title="24&#x20;HR&#x20;paliperidone&#x20;1.5&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                     data-slideorder="6"                                                     data-ndccode="50458-0554-01"                                                     data-standardname="24&#x20;HR&#x20;paliperidone&#x20;1.5&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                     data-shape="OVAL"                                                     data-size="11mm"                                                     data-color="ORANGE"                                                     data-scored="1"                                                     data-imprint="PALI&#x3b;1.5"                                                     data-photo-type="drug" >                                                        <img id="zoom_7"                                                             title="24&#x20;HR&#x20;paliperidone&#x20;1.5&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                             alt="24&#x20;HR&#x20;paliperidone&#x20;1.5&#x20;MG&#x20;Extended&#x20;Release&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                             data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0554-01_NLMIMAGE10_E415F27F.jpg"                                                             src="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0554-01_NLMIMAGE10_E415F27F.jpg"                                                             />                                                        <span class="enlarge"></span>                                                    </a>                                                 </li>                                                                                                                                                                           	                                            											                                                                                                                                                                                                                                                                                                                                                                	<li class="img drug-photo">                                                    <p>50458-0550-01</p>                                                                                                                                                            <a href="/rximage.nlm.nih.gov/image/images/gallery/original/50458-0550-01_NLMIMAGE10_343E1A40.jpg"                                                      class="thumbnail"                                                      title="24&#x20;HR&#x20;paliperidone&#x20;3&#x20;MG&#x20;Extended&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                     data-slideorder="7"                                                     data-ndccode="50458-0550-01"                                                     data-standardname="24&#x20;HR&#x20;paliperidone&#x20;3&#x20;MG&#x20;Extended&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                     data-shape="OVAL"                                                     data-size="11mm"                                                     data-color="WHITE"                                                     data-scored="1"                                                     data-imprint="PAL&#x3b;3"                                                     data-photo-type="drug" >                                                        <img id="zoom_8"                                                             title="24&#x20;HR&#x20;paliperidone&#x20;3&#x20;MG&#x20;Extended&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                             alt="24&#x20;HR&#x20;paliperidone&#x20;3&#x20;MG&#x20;Extended&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Invega&#x5d;"                                                             data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0550-01_NLMIMAGE10_343E1A40.jpg"                                                             src="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0550-01_NLMIMAGE10_343E1A40.jpg"                                                             />                                                        <span class="enlarge"></span>                                                    </a>                                                 </li>                                                                                                 </ul>                                                 </li>                                                                                                                                                                            </ul>                                         </div>                                                                     </div>                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                                                                                                    <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22paliperidone%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=paliperidone" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=paliperidone" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=paliperidone[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=paliperidone/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=paliperidone/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=paliperidone/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=paliperidone[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=paliperidone&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    50458-550-01,                                                                                                                                        	                                    50458-550-10,                                                                                                                                        	                                    50458-550-98,                                                                                                                                        	                                    50458-551-01,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    50458-551-10,                                                                                                                                        	                                    50458-551-98,                                                                                                                                        	                                    50458-552-01,                                                                                                                                        	                                    50458-552-10,                                                                                                                                        	                                    50458-552-98,                                                                                                                                        	                                    50458-554-01,                                                                                                                                        	                                    50458-554-10,                                                                                                                                        	                                    50458-554-98                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Janssen Pharmaceuticals, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                                   </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                                                                            <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	05/14                                                                                                     </p>                                                                                                                                                     <p class="orangetext">If you are a consumer or patient please visit <a class="audience-context-switch consumer" href="dailymed/drugInfo.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a download class="pdf" href="dailymed/getFile.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&amp;type=pdf&amp;name=7b8e5b26-b9e4-4704-921b-3c3c0d159916" target="_blank">PDF</a>                                                    	<a download class="xml" href="dailymed/getFile.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&amp;type=zip&amp;name=INVEGA" target="_blank">XML</a>                                                    </li>                                                                                                                                                            <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="BOX"></a>  <a name="section-1"></a>   <p></p>   <h1> <span class="Emphasis">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</span> </h1>   <p class="First"> <span class="Bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets is not approved for the treatment of patients with dementia-related psychosis. <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span></span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use INVEGA   <span class="Sup">&reg;</span> safely and effectively. See full prescribing information for INVEGA   <span class="Sup">&reg;</span>.   <br />    <br /> INVEGA   <span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets   <br />    <br /> Initial U.S. Approval: 2006  </div>   <div class="Warning">    <div>     <h1 class="Warning"> <span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</span> </h1>     <h1 class="Warning"> <span class="Bold Italics">See <a href="#BOX">full prescribing information for complete boxed warning</a>.</span> </h1>     <p class="Highlighta"> <span class="Bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA<span class="Sup">&reg; </span>is not approved for use in patients with dementia-related psychosis. (<a href="#S5.1">5.1</a>)</span> </p>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">INVEGA<span class="Sup">&reg;</span> is an atypical antipsychotic agent indicated for </p>     <p class="Highlighta">Treatment of schizophrenia (<a href="#S1.1">1.1</a>) </p>     <ul>      <li>Adults: Efficacy was established in three 6-week trials and one maintenance trial. (<a href="#S14.1">14.1</a>)</li>      <li>Adolescents (ages 12–17): Efficacy was established in one 6-week trial. (<a href="#S14.1">14.1</a>)</li>     </ul>     <p class="Highlighta">Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. (<a href="#S1.2">1.2</a>) </p>     <ul class="Disc">      <li>Efficacy was established in two 6-week trials in adult patients. (<a href="#S14.2">14.2</a>)</li>     </ul>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <table width="85%">      <colgroup>      <col align="left" valign="top" width="32%" />       <col align="center" valign="bottom" width="20%" />       <col align="center" valign="bottom" width="14%" />       <col align="center" valign="bottom" width="18%" />       <col align="center" valign="bottom" width="16%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Lrule Rrule" align="left" colspan="2"></th>       <th class="Rrule" align="center">Initial Dose</th>       <th class="Rrule" align="center">Recommended Dose</th>       <th class="Rrule" align="center">Maximum Dose</th>       </tr>      </thead>      <tbody>       <tr class="First">        <td class="Botrule Lrule Rrule" align="left" colspan="2">Schizophrenia - adults (<a href="#S2.1">2.1</a>)</td>       <td class="Botrule Rrule" align="center">6 mg/day</td>       <td class="Botrule Rrule" align="center">3 – 12 mg/day</td>       <td class="Botrule Rrule" align="center">12 mg/day</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left" rowspan="2" valign="middle">Schizophrenia-adolescents (<a href="#S2.1">2.1</a>)</td>       <td class="Rrule" align="center" valign="bottom">Weight &lt; 51kg</td>       <td class="Rrule" align="center">3 mg/day</td>       <td class="Rrule" align="center">3 – 6 mg/day</td>       <td class="Rrule" align="center">6 mg/day</td>       </tr>       <tr class="Botrule">        <td class="Rrule" align="center" valign="bottom">Weight ≥ 51kg</td>       <td class="Rrule" align="center">3 mg/day</td>       <td class="Rrule" align="center">3 – 12 mg/day</td>       <td class="Rrule" align="center">12 mg/day</td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" align="left" colspan="2" valign="bottom">Schizoaffective disorder - adults (<a href="#S2.2">2.2</a>)</td>       <td class="Rrule" align="center">6 mg/day</td>       <td class="Rrule" align="center">3 – 12 mg/day</td>       <td class="Rrule" align="center">12 mg/day</td>       </tr>      </tbody>     </table>     <ul>      <li>Tablet should be swallowed whole and should not be chewed, divided, or crushed. (<a href="#S2.3">2.3</a>)</li>     </ul>    </div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">Tablets: 1.5 mg, 3 mg, 6 mg, and 9 mg (<a href="#S3">3</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <p class="Highlighta">Known hypersensitivity to paliperidone, risperidone, or to any components in the formulation. (<a href="#S4">4</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Italics">Cerebrovascular Adverse Reactions: </span>An increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack, including fatalities) has been seen in elderly patients with dementia- related psychoses treated with atypical antipsychotics. (<a href="#S5.2">5.2</a>)</li>      <li> <span class="Italics">Neuroleptic Malignant Syndrome:</span> Manage with immediate discontinuation of drug and close monitoring. (<a href="#S5.3">5.3</a>)</li>      <li> <span class="Italics">QT Prolongation: </span>Increase in QT interval, avoid use with drugs that also increase QT interval and in patients with risk factors for prolonged QT interval. (<a href="#S5.4">5.4</a>)</li>      <li> <span class="Italics">Tardive Dyskinesia:</span> Discontinue drug if clinically appropriate. (<a href="#S5.5">5.5</a>)</li>      <li> <span class="Italics">Metabolic Changes:</span> Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. (<a href="#S5.6">5.6</a>)      <ul class="Circle">        <li> <span class="Italics">Hyperglycemia and Diabetes Mellitus:</span> Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (<a href="#S5.6">5.6</a>)</li>        <li> <span class="Italics">Dyslipidemia:</span> Undesirable alterations have been observed in patients treated with atypical antipsychotics. (<a href="#S5.6">5.6</a>)</li>        <li> <span class="Italics">Weight Gain:</span> Significant weight gain has been reported. Monitor weight gain. (<a href="#S5.6">5.6</a>)</li>       </ul> </li>      <li> <span class="Italics">Hyperprolactinemia:</span> Prolactin elevations occur and persist during chronic administration. (<a href="#S5.7">5.7</a>)</li>      <li> <span class="Italics">Gastrointestinal Narrowing: </span> Obstructive symptoms may result in patients with gastrointestinal disease. (<a href="#S5.8">5.8</a>)</li>      <li> <span class="Italics">Orthostatic Hypotension and Syncope: </span> Use with caution in patients with known cardiovascular or cerebrovascular disease and patients predisposed to hypotension. (<a href="#S5.9">5.9</a>)</li>      <li> <span class="Italics">Leukopenia, Neutropenia, and Agranulocytosis:</span> has been reported with antipsychotics, including INVEGA<span class="Sup">&reg;</span>. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of INVEGA<span class="Sup">&reg;</span> should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. (<a href="#S5.10">5.10</a>)</li>      <li> <span class="Italics">Potential for Cognitive and Motor Impairment:</span> Use caution when operating machinery. (<a href="#S5.11">5.11</a>)</li>      <li> <span class="Italics">Seizures: </span> Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. (<a href="#S5.12">5.12</a>)</li>      <li> <span class="Italics">Suicide: </span> Closely supervise high-risk patients. (<a href="#S5.14">5.14</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div>      <div></div>      <div></div>     </div>    </div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Commonly observed adverse reactions (incidence ≥ 5% and at least twice that for placebo) were (<a href="#S6">6</a>) </p>     <ul>      <li>Adults with schizophrenia: extrapyramidal symptoms, tachycardia, and akathisia.</li>      <li>Adolescents with schizophrenia: somnolence, akathisia, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, and tachycardia.</li>      <li>Adults with schizoaffective disorder: extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis.</li>     </ul>     <br />     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch </span> </p>    </div>    <div></div>    <div>     <div></div>     <div></div>    </div>    <div>     <div></div>    </div>    <div>     <div></div>     <div></div>    </div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div>     <div>      <div></div>     </div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul>      <li>Centrally-acting drugs: Due to CNS effects, use caution in combination. Avoid alcohol. (<a href="#S7.1">7.1</a>)</li>      <li>Drugs that may cause orthostatic hypotension: An additive effect may be observed when co-administered with INVEGA<span class="Sup">&reg;</span>. (<a href="#S7.1">7.1</a>)</li>      <li>Strong CYP3A4/P-glycoprotein (P-gp) inducers: It may be necessary to increase the dose of INVEGA<span class="Sup">&reg;</span> when a strong inducer of both CYP3A4 and P-gp (e.g., carbamazepine) is co-administered. Conversely, on discontinuation of the strong inducer, it may be necessary to decrease the dose of INVEGA<span class="Sup">&reg;</span>. (<a href="#S7.2">7.2</a>)</li>      <li>Co-administration of divalproex sodium increased Cmax and AUC of paliperidone by approximately 50%. Adjust dose of INVEGA<span class="Sup">&reg;</span> if necessary based on clinical assessment. (<a href="#S7.2">7.2</a>)</li>     </ul>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <ul>      <li>Renal impairment: Dosing must be individualized according to renal function status. (<a href="#S2.5">2.5</a>)</li>      <li>Elderly: Same as for younger adults (adjust dose according to renal function status). (<a href="#S2.4">2.4</a>)</li>      <li>Nursing Mothers: The benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone. (<a href="#S8.3">8.3</a>)</li>      <li>Pediatric Use: Safety and effectiveness in the treatment of schizophrenia not established in patients less than 12 years of age. Safety and effectiveness in the treatment of schizoaffective disorder not established in patients less than 18 years of age. (<a href="#S8.4">8.4</a>)</li>     </ul>    </div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>    </div>   </div>   <div>    <div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div>     <div></div>     <div></div>    </div>    <div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>   <p class="HighlightsRevision">Revised: 4/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc"><span class="Emphasis">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</span></a> </h1>   <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Schizophrenia</a> </h2>   <h2> <a href="#section-1.2" class="toc">1.2 Schizoaffective Disorder</a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 Schizophrenia</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Schizoaffective Disorder</a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Administration Instructions</a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Use with Risperidone</a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Dosage in Special Populations</a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis</a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients With Dementia-Related Psychosis</a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Neuroleptic Malignant Syndrome</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 QT Prolongation</a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Tardive Dyskinesia</a> </h2>   <h2> <a href="#section-5.6" class="toc">5.6 Metabolic Changes</a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Hyperprolactinemia</a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Potential for Gastrointestinal Obstruction</a> </h2>   <h2> <a href="#section-5.9" class="toc">5.9 Orthostatic Hypotension and Syncope</a> </h2>   <h2> <a href="#section-5.10" class="toc">5.10 Leukopenia, Neutropenia, and Agranulocytosis</a> </h2>   <h2> <a href="#section-5.11" class="toc">5.11 Potential for Cognitive and Motor Impairment</a> </h2>   <h2> <a href="#section-5.12" class="toc">5.12 Seizures</a> </h2>   <h2> <a href="#section-5.13" class="toc">5.13 Dysphagia</a> </h2>   <h2> <a href="#section-5.14" class="toc">5.14 Suicide</a> </h2>   <h2> <a href="#section-5.15" class="toc">5.15 Priapism</a> </h2>   <h2> <a href="#section-5.16" class="toc">5.16 Thrombotic Thrombocytopenic Purpura (TTP)</a> </h2>   <h2> <a href="#section-5.17" class="toc">5.17 Body Temperature Regulation</a> </h2>   <h2> <a href="#section-5.18" class="toc">5.18 Antiemetic Effect</a> </h2>   <h2> <a href="#section-5.19" class="toc">5.19 Use in Patients with Concomitant Illness</a> </h2>   <h2> <a href="#section-5.20" class="toc">5.20 Monitoring: Laboratory Tests</a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Overall Adverse Reaction Profile</a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizophrenia in Adults and Adolescents</a> </h2>   <h2> <a href="#section-6.3" class="toc">6.3 Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizoaffective Disorder in Adults</a> </h2>   <h2> <a href="#section-6.4" class="toc">6.4 Discontinuations Due to Adverse Reactions</a> </h2>   <h2> <a href="#section-6.5" class="toc">6.5 Dose-Related Adverse Reactions</a> </h2>   <h2> <a href="#section-6.6" class="toc">6.6 Demographic Differences</a> </h2>   <h2> <a href="#section-6.7" class="toc">6.7 Extrapyramidal Symptoms (EPS)</a> </h2>   <h2> <a href="#section-6.8" class="toc">6.8 Laboratory Test Abnormalities</a> </h2>   <h2> <a href="#section-6.9" class="toc">6.9 Other Adverse Reactions Observed During Premarketing Evaluation of INVEGA<span class="Sup">&reg;</span></a> </h2>   <h2> <a href="#section-6.10" class="toc">6.10 Postmarketing Experience</a> </h2>   <h2> <a href="#section-6.11" class="toc">6.11 Adverse Reactions Reported With Risperidone</a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Potential for INVEGA<span class="Sup">&reg;</span> to Affect Other Drugs</a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Potential for Other Drugs to Affect INVEGA<span class="Sup">&reg;</span></a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 Renal Impairment</a> </h2>   <h2> <a href="#section-8.6" class="toc">8.7 Hepatic Impairment</a> </h2>   <h1> <a href="#section-9" class="toc">9 DRUG ABUSE AND DEPENDENCE</a> </h1>   <h2> <a href="#section-9.1" class="toc">9.1 Controlled Substance</a> </h2>   <h2> <a href="#section-9.2" class="toc">9.2 Abuse</a> </h2>   <h2> <a href="#section-9.3" class="toc">9.3 Dependence</a> </h2>   <h1> <a href="#section-10" class="toc">10 OVERDOSAGE</a> </h1>   <h2> <a href="#section-10.1" class="toc">10.1 Human Experience</a> </h2>   <h2> <a href="#section-10.2" class="toc">10.2 Management of Overdosage</a> </h2>   <h1> <a href="#section-11" class="toc">11 DESCRIPTION</a> </h1>   <h2> <a href="#section-11.1" class="toc">11.1 Delivery System Components and Performance</a> </h2>   <h1> <a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-14" class="toc">14 CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-14.1" class="toc">14.1 Schizophrenia</a> </h2>   <h2> <a href="#section-14.2" class="toc">14.2 Schizoaffective Disorder</a> </h2>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <h2> <a href="#section-16.1" class="toc">17.1 Orthostatic Hypotension</a> </h2>   <h2> <a href="#section-16.2" class="toc">17.2 Interference with Cognitive and Motor Performance</a> </h2>   <h2> <a href="#section-16.3" class="toc">17.3 Pregnancy</a> </h2>   <h2> <a href="#section-16.4" class="toc">17.4 Nursing</a> </h2>   <h2> <a href="#section-16.5" class="toc">17.5 Concomitant Medication</a> </h2>   <h2> <a href="#section-16.6" class="toc">17.6 Alcohol</a> </h2>   <h2> <a href="#section-16.7" class="toc">17.7 Heat Exposure and Dehydration</a> </h2>   <h2> <a href="#section-16.8" class="toc">17.8 Administration</a> </h2>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="S1"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S1.1"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Schizophrenia</h2>    <p class="First"> INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets are indicated for the treatment of schizophrenia <span class="Italics">[see<a href="#S14.1"> Clinical Studies (14.1)</a>]</span>.</p>    <p> The efficacy of INVEGA<span class="Sup">&reg;</span> in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S1.2"></a>   <a name="section-1.2"></a>    <p></p>    <h2>1.2 Schizoaffective Disorder</h2>    <p class="First"> INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy <span class="Italics"> [see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>    <p> The efficacy of INVEGA<span class="Sup">&reg;</span> in schizoaffective disorder was established in two 6-week trials in adults.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="S2"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 Schizophrenia</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.1.1"></a>     <p></p>     <p class="First">Adults</p>     <p> The recommended dose of INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets for the treatment of schizophrenia in adults is 6 mg administered once daily. Initial dose titration is not required. Although it has not been systematically established that doses above 6 mg have additional benefit, there was a general trend for greater effects with higher doses. This must be weighed against the dose-related increase in adverse reactions. Thus, some patients may benefit from higher doses, up to 12 mg/day, and for some patients, a lower dose of 3 mg/day may be sufficient. Dose increases above 6 mg/day should be made only after clinical reassessment and generally should occur at intervals of more than 5 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day.</p>     <p> In a longer-term study, INVEGA<span class="Sup">&reg;</span> has been shown to be effective in delaying time to relapse in patients with schizophrenia who were stabilized on INVEGA<span class="Sup">&reg;</span> for 6 weeks <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. INVEGA<span class="Sup">&reg;</span> should be prescribed at the lowest effective dose for maintaining clinical stability and the physician should periodically reevaluate the long-term usefulness of the drug in individual patients.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.1.2"></a>     <p></p>     <p class="First">Adolescents (12–17 years of age)</p>     <p>The recommended starting dose of INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets for the treatment of schizophrenia in adolescents 12–17 years of age is 3 mg administered once daily. Initial dose titration is not required. Dose increases, if considered necessary, should be made only after clinical reassessment and should occur at increments of 3 mg/day at intervals of more than 5 days. Prescribers should be mindful that, in the adolescent schizophrenia study, there was no clear enhancement to efficacy at the higher doses, i.e., 6 mg for subjects weighing less than 51 kg and 12 mg for subjects weighing 51 kg or greater, while adverse events were dose-related.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Schizoaffective Disorder</h2>    <p class="First">The recommended dose of INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets for the treatment of schizoaffective disorder in adults is 6 mg administered once daily. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended dose range of 3 to 12 mg once daily. A general trend for greater effects was seen with higher doses. This trend must be weighed against dose-related increase in adverse reactions. Dosage adjustment, if indicated, should occur only after clinical reassessment. Dose increases, if indicated, generally should occur at intervals of more than 4 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.3"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Administration Instructions</h2>    <p class="First">INVEGA<span class="Sup">&reg; </span>can be taken with or without food.</p>    <p>INVEGA<span class="Sup">&reg;</span> must be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.4"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Use with Risperidone</h2>    <p class="First">Concomitant use of INVEGA<span class="Sup">&reg;</span> with risperidone has not been studied. Since paliperidone is the major active metabolite of risperidone, consideration should be given to the additive paliperidone exposure if risperidone is coadministered with INVEGA<span class="Sup">&reg;</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.5"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Dosage in Special Populations</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="Renal"></a>    <a name="section-2.5.1"></a>     <p></p>     <p class="First"> <span class="Underline">Renal Impairment</span> </p>     <p>Dosing must be individualized according to the patient's renal function status. For patients with mild renal impairment (creatinine clearance ≥ 50 mL/min to &lt; 80 mL/min), the recommended initial dose of INVEGA<span class="Sup">&reg;</span> is 3 mg once daily. The dose may then be increased to a maximum of 6 mg once daily based on clinical response and tolerability. For patients with moderate to severe renal impairment (creatinine clearance ≥ 10 mL/min to &lt; 50 mL/min), the recommended initial dose of INVEGA<span class="Sup">&reg;</span> is 1.5 mg once daily, which may be increased to a maximum of 3 mg once daily after clinical reassessment. As INVEGA<span class="Sup">&reg;</span> has not been studied in patients with creatinine clearance below 10 mL/min, use is not recommended in such patients.<span class="Italics"> [See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.5.2"></a>     <p></p>     <p class="First"> <span class="Underline">Hepatic Impairment</span> </p>     <p>For patients with mild to moderate hepatic impairment, (Child-Pugh Classification A and B), no dose adjustment is recommended <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. INVEGA<span class="Sup">&reg;</span> has not been studied in patients with severe hepatic impairment.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.5.3"></a>     <p></p>     <p class="First"> <span class="Underline">Elderly</span> </p>     <p>Because elderly patients may have diminished renal function, dose adjustments may be required according to their renal function status. In general, recommended dosing for elderly patients with normal renal function is the same as for younger adult patients with normal renal function. For patients with moderate to severe renal impairment (creatinine clearance 10 mL/min to &lt; 50 mL/min), the maximum recommended dose of INVEGA<span class="Sup">&reg;</span> is 3 mg once daily <span class="Italics">[see <a href="#Renal">Renal Impairment above</a>]</span>.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="S3"></a>  <a name="section-3"></a>   <p></p>    <p class="First">INVEGA<span class="Sup">&reg;</span> Extended-Release Tablets are available in the following strengths and colors: 1.5 mg (orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink). All tablets are capsule shaped and are imprinted with either &quot;PAL 1.5&quot;, &quot;PAL 3&quot;, &quot;PAL 6&quot;, or &quot;PAL 9&quot;.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="S4"></a>  <a name="section-4"></a>   <p></p>    <p class="First">Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. INVEGA<span class="Sup">&reg;</span> (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in INVEGA<span class="Sup">&reg;</span>.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="S5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S5.1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis</h2>    <p class="First"> <span class="Bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA<span class="Sup">&reg;</span> (paliperidone) is not approved for the treatment of dementia-related psychosis <span class="Italics">[see <a href="#BOX">Boxed Warning</a>]</span>.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.2"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients With Dementia-Related Psychosis</h2>    <p class="First">In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. INVEGA<span class="Sup">&reg;</span> was not marketed at the time these studies were performed. INVEGA<span class="Sup">&reg;</span> is not approved for the treatment of patients with dementia-related psychosis <span class="Italics">[see also <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.3"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Neuroleptic Malignant Syndrome</h2>    <p class="First">A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</p>    <p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.</p>    <p>The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>    <p>If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.4"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 QT Prolongation</h2>    <p class="First">Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.</p>    <p>Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.</p>    <p>The effects of paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.</p>    <p>In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate-release was more than twice the exposure observed with the maximum recommended 12 mg dose of INVEGA<span class="Sup">&reg;</span> (C<span class="Sub">max</span> ss = 113 ng/mL and 45 ng/mL, respectively, when administered with a standard breakfast). In this same study, a 4 mg dose of the immediate-release oral formulation of paliperidone, for which C<span class="Sub">max</span> ss = 35 ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% CI: 3.6; 10.1) on day 2 at 1.5 hours post-dose. None of the subjects had a change exceeding 60 msec or a QTcLD exceeding 500 msec at any time during this study.</p>    <p>For the three fixed-dose efficacy studies in subjects with schizophrenia, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the INVEGA<span class="Sup">&reg;</span> 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec). No subject receiving INVEGA<span class="Sup">&reg;</span> had a QTcLD exceeding 500 msec at any time in any of these three studies.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.5"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Tardive Dyskinesia</h2>    <p class="First">A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.</p>    <p>The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.</p>    <p>There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.</p>    <p>Given these considerations, INVEGA<span class="Sup">&reg;</span> should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>    <p>If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA<span class="Sup">&reg;</span>, drug discontinuation should be considered. However, some patients may require treatment with INVEGA<span class="Sup">&reg;</span> despite the presence of the syndrome.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.6"></a>   <a name="section-5.6"></a>    <p></p>    <h2>5.6 Metabolic Changes</h2>    <p class="First">Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.6.1"></a>     <p></p>     <p class="First">Hyperglycemia and Diabetes Mellitus</p>     <p>Hyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA<span class="Sup">&reg;</span>. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because INVEGA<span class="Sup">&reg;</span> was not marketed at the time these studies were performed, it is not known if INVEGA<span class="Sup">&reg;</span> is associated with this increased risk.</p>     <p> Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.</p>     <p> Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia are presented in Table 1a.</p>     <div class="scrollingtable">     <table width="90%">       <caption>        <span>Table 1a. Change in Fasting Glucose from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia</span>       </caption>       <colgroup>       <col align="left" valign="bottom" width="30%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />       </colgroup>      <thead>        <tr class="First">         <th align="left"></th>        <th align="center"></th>        <th align="center"></th>        <th align="center" colspan="2"> INVEGA<span class="Sup">&reg;</span></th>        <th align="center"></th>        </tr>        <tr class="Last">         <th align="left"></th>        <th align="center">Placebo</th>        <th align="center">3 mg/day</th>        <th align="center">6 mg/day</th>        <th align="center">9 mg/day</th>        <th align="center">12 mg/day</th>        </tr>       </thead>       <tbody>        <tr class="First">         <td align="left"></td>        <td align="center" colspan="5" valign="middle"><span class="Bold">Mean change from baseline (mg/dL)</span></td>        </tr>        <tr>         <td align="left"></td>        <td align="center"><span class="Bold">n=322</span></td>        <td align="center"><span class="Bold">n=122</span></td>        <td align="center"><span class="Bold">n=212</span></td>        <td align="center"><span class="Bold">n=234</span></td>        <td align="center"><span class="Bold">n=218</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Serum Glucose<br />Change from baseline</span></td>        <td align="center">0.8</td>        <td align="center">-0.7</td>        <td align="center">0.4</td>        <td align="center">2.3</td>        <td align="center">4.3</td>        </tr>        <tr>         <td align="left"></td>        <td align="center" colspan="5" valign="middle"><span class="Bold">Proportion of Patients with Shifts</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Serum Glucose<br />Normal to High</span></td>        <td align="center">5.1%</td>        <td align="center">3.2%</td>        <td align="center">4.5%</td>        <td align="center">4.8%</td>        <td align="center">3.8%</td>        </tr>        <tr class="Last">         <td align="left">(&lt;100 mg/dL to ≥126 mg/dL)</td>        <td align="center">(12/236)</td>        <td align="center">(3/93)</td>        <td align="center">(7/156)</td>        <td align="center">(9/187)</td>        <td align="center">(6/157)</td>        </tr>       </tbody>      </table>    </div>     <p>In the uncontrolled, longer-term open-label extension studies, INVEGA<span class="Sup">&reg;</span> was associated with a mean change in glucose of +3.3 mg/dL at Week 24 (n=570) and +4.6 mg/dL at Week 52 (n=314).</p>     <p>Data from the placebo-controlled 6-week study in adolescent subjects (12–17 years of age) with schizophrenia are presented in Table 1b.</p>     <div class="scrollingtable">     <table width="90%">       <caption>        <span>Table 1b. Change in Fasting Glucose from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia</span>       </caption>       <colgroup>       <col align="left" valign="bottom" width="30%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />        <col align="center" valign="bottom" width="14%" />       </colgroup>      <thead>        <tr class="First">         <th align="left"></th>        <th align="center"></th>        <th align="center" colspan="4">INVEGA<span class="Sup">&reg;</span></th>        </tr>        <tr class="Last">         <th align="left"></th>        <th align="center">Placebo</th>        <th align="center">1.5 mg/day</th>        <th align="center">3 mg/day</th>        <th align="center">6 mg/day</th>        <th align="center">12 mg/day</th>        </tr>       </thead>       <tbody>        <tr class="First">         <td align="left"></td>        <td align="center" colspan="5" valign="middle"><span class="Bold">Mean change from baseline (mg/dL)</span></td>        </tr>        <tr>         <td align="left"></td>        <td align="center"><span class="Bold">n=41</span></td>        <td align="center"><span class="Bold">n=44</span></td>        <td align="center"><span class="Bold">n=11</span></td>        <td align="center"><span class="Bold">n=28</span></td>        <td align="center"><span class="Bold">n=32</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Serum Glucose<br />Change from baseline</span></td>        <td align="center">0.8</td>        <td align="center">-1.4</td>        <td align="center">-1.8</td>        <td align="center">-0.1</td>        <td align="center">5.2</td>        </tr>        <tr>         <td align="left"></td>        <td align="center" colspan="5" valign="middle"><span class="Bold">Proportion of Patients with Shifts</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Serum Glucose<br />Normal to High</span></td>        <td align="center">3%</td>        <td align="center">0%</td>        <td align="center">0%</td>        <td align="center">0%</td>        <td align="center">11%</td>        </tr>        <tr class="Last">         <td align="left">(&lt;100 mg/dL to ≥126 mg/dL)</td>        <td align="center">(1/32)</td>        <td align="center">(0/34)</td>        <td align="center">(0/9)</td>        <td align="center">(0/20)</td>        <td align="center">(3/27)</td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.6.2"></a>     <p></p>     <p class="First"> <span class="Underline">Dyslipidemia</span> </p>     <p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.</p>     <p>Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia are presented in Table 2a.</p>     <div class="scrollingtable">     <table width="90%">       <caption>        <span>Table 2a. Change in Fasting Lipids from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia</span>       </caption>       <colgroup>       <col align="left" valign="bottom" width="30%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />       </colgroup>      <thead>        <tr class="First">         <th align="left"></th>        <th align="center"></th>        <th align="center" colspan="4"> INVEGA<span class="Sup">&reg;</span></th>        </tr>        <tr class="Last">         <th align="left"></th>        <th align="center">Placebo</th>        <th align="center">3 mg/day</th>        <th align="center">6 mg/day</th>        <th align="center">9 mg/day</th>        <th align="center">12 mg/day</th>        </tr>       </thead>       <tbody>        <tr class="First">         <td align="left"></td>        <td align="center" colspan="5"><span class="Bold">Mean change from baseline (mg/dL)</span></td>        </tr>        <tr>         <td align="left" valign="bottom"><span class="Bold">Cholesterol </span></td>        <td align="center"><span class="Bold">n=331</span></td>        <td align="center"><span class="Bold">n=120</span></td>        <td align="center"><span class="Bold">n=216</span></td>        <td align="center"><span class="Bold">n=236</span></td>        <td align="center"><span class="Bold">n=231</span></td>        </tr>        <tr>         <td align="left" valign="bottom"><span class="Bold">Change from baseline</span></td>        <td align="center">-6.3</td>        <td align="center">-4.4</td>        <td align="center">-2.4</td>        <td align="center">-5.3</td>        <td align="center">-4.0</td>        </tr>        <tr>         <td align="left"><span class="Bold">LDL </span></td>        <td align="center"><span class="Bold">n=322</span></td>        <td align="center"><span class="Bold">n=116</span></td>        <td align="center"><span class="Bold">n=210</span></td>        <td align="center"><span class="Bold">n=231</span></td>        <td align="center"><span class="Bold">n=225</span></td>        </tr>        <tr>         <td align="left"><span class="Bold"> Change from baseline</span></td>        <td align="center">-3.2</td>        <td align="center">0.5</td>        <td align="center">-0.8</td>        <td align="center">-3.9</td>        <td align="center">-2.0</td>        </tr>        <tr>         <td align="left"><span class="Bold">HDL</span></td>        <td align="center"><span class="Bold">n=331</span></td>        <td align="center"><span class="Bold">n=119</span></td>        <td align="center"><span class="Bold">n=216</span></td>        <td align="center"><span class="Bold">n=234</span></td>        <td align="center"><span class="Bold">n=230</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Change from baseline</span></td>        <td align="center">0.3</td>        <td align="center">-0.4</td>        <td align="center">0.5</td>        <td align="center">0.8</td>        <td align="center">1.2</td>        </tr>        <tr>         <td align="left"><span class="Bold">Triglycerides </span></td>        <td align="center"><span class="Bold">n=331</span></td>        <td align="center"><span class="Bold">n=120</span></td>        <td align="center"><span class="Bold">n=216</span></td>        <td align="center"><span class="Bold">n=236</span></td>        <td align="center"><span class="Bold">n=231</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Change from baseline</span></td>        <td align="center">-22.3</td>        <td align="center">-18.3</td>        <td align="center">-12.6</td>        <td align="center">-10.6</td>        <td align="center">-15.4</td>        </tr>        <tr>         <td align="left"></td>        <td align="center" colspan="5"><span class="Bold">Proportion of Patients with Shifts</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Cholesterol</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to High</span></td>        <td align="center">2.6%</td>        <td align="center">2.8%</td>        <td align="center">5.6%</td>        <td align="center">4.1%</td>        <td align="center">3.1%</td>        </tr>        <tr>         <td align="left"><span class="Bold">(&lt;200 mg/dL to ≥240 mg/dL)</span></td>        <td align="center">(5/194)</td>        <td align="center">(2/71)</td>        <td align="center">(7/125)</td>        <td align="center">(6/147)</td>        <td align="center">(4/130)</td>        </tr>        <tr>         <td align="left"><span class="Bold">LDL</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to High</span></td>        <td align="center">1.9%</td>        <td align="center">0.0%</td>        <td align="center">5.0%</td>        <td align="center">3.7%</td>        <td align="center">0.0%</td>        </tr>        <tr>         <td align="left"><span class="Bold">(&lt;100 mg/dL to ≥160 mg/dL)</span></td>        <td align="center">(2/105)</td>        <td align="center">(0/44)</td>        <td align="center">(3/60)</td>        <td align="center">(3/81)</td>        <td align="center">(0/69)</td>        </tr>        <tr>         <td align="left"><span class="Bold">HDL</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to Low</span></td>        <td align="center">22.0%</td>        <td align="center">16.3%</td>        <td align="center">29.1%</td>        <td align="center">23.4%</td>        <td align="center">20.0%</td>        </tr>        <tr>         <td align="left"><span class="Bold">( ≥40 mg/dL to &lt;40 mg/dL)</span></td>        <td align="center">(44/200)</td>        <td align="center">(13/80)</td>        <td align="center">(39/134)</td>        <td align="center">(32/137)</td>        <td align="center">(27/135)</td>        </tr>        <tr>         <td align="left"><span class="Bold">Triglycerides</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to High</span></td>        <td align="center">5.3%</td>        <td align="center">11.0%</td>        <td align="center">8.8%</td>        <td align="center">8.7%</td>        <td align="center">4.3%</td>        </tr>        <tr class="Last">         <td align="left"><span class="Bold">(&lt;150 mg/dL to ≥200 mg/dL)</span></td>        <td align="center">(11/208)</td>        <td align="center">(9/82)</td>        <td align="center">(12/136)</td>        <td align="center">(13/150)</td>        <td align="center">(6/139)</td>        </tr>       </tbody>      </table>    </div>     <p>In the uncontrolled, longer-term open-label extension studies, INVEGA<span class="Sup">&reg;</span> was associated with a mean change in (a) total cholesterol of -1.5 mg/dL at Week 24 (n=573) and -1.5 mg/dL at Week 52 (n=317), (b) triglycerides of -6.4 mg/dL at Week 24 (n=573) and -10.5 mg/dL at Week 52 (n=317); (c) LDL of -1.9 mg/dL at Week 24 (n=557) and -2.7 mg/dL at Week 52 (n=297); and (d) HDL of +2.2 mg/dL at Week 24 (n=568) and +3.6 mg/dL at Week 52 (n=302).</p>     <p>Data from the placebo-controlled 6-week study in adolescent subjects (12–17 years of age) with schizophrenia are presented in Table 2b.</p>     <div class="scrollingtable">     <table width="90%">       <caption>        <span>Table 2b. Change in Fasting Lipids from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia</span>       </caption>       <colgroup>       <col align="left" valign="bottom" width="30%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />        <col align="center" valign="middle" width="14%" />       </colgroup>      <thead>        <tr class="First">         <th align="left"></th>        <th align="center"></th>        <th align="center" colspan="4"> INVEGA<span class="Sup">&reg;</span></th>        </tr>        <tr class="Last">         <th align="left"></th>        <th align="center">Placebo</th>        <th align="center">1.5 mg/day</th>        <th align="center">3 mg/day</th>        <th align="center">6 mg/day</th>        <th align="center">12 mg/day</th>        </tr>       </thead>       <tbody>        <tr class="First">         <td align="left"></td>        <td align="center" colspan="5"><span class="Bold">Mean change from baseline (mg/dL)</span></td>        </tr>        <tr>         <td align="left" valign="bottom"><span class="Bold">Cholesterol</span></td>        <td align="center"><span class="Bold">n=39</span></td>        <td align="center"><span class="Bold">n=45</span></td>        <td align="center"><span class="Bold">n=11</span></td>        <td align="center"><span class="Bold">n=28</span></td>        <td align="center"><span class="Bold">n=32</span></td>        </tr>        <tr>         <td align="left" valign="bottom"><span class="Bold">Change from baseline</span></td>        <td align="center">-7.8</td>        <td align="center">-3.3</td>        <td align="center">12.7</td>        <td align="center">3.0</td>        <td align="center">-1.5</td>        </tr>        <tr>         <td align="left"><span class="Bold">LDL</span></td>        <td align="center"><span class="Bold">n=37</span></td>        <td align="center"><span class="Bold">n=40</span></td>        <td align="center"><span class="Bold">n=9</span></td>        <td align="center"><span class="Bold">n=27</span></td>        <td align="center"><span class="Bold">n=31</span></td>        </tr>        <tr>         <td align="left"><span class="Bold"> Change from baseline</span></td>        <td align="center">-4.1</td>        <td align="center">-3.1</td>        <td align="center">7.2</td>        <td align="center">2.4</td>        <td align="center">0.6</td>        </tr>        <tr>         <td align="left"><span class="Bold">HDL</span></td>        <td align="center"><span class="Bold">n=37</span></td>        <td align="center"><span class="Bold">n=41</span></td>        <td align="center"><span class="Bold">n=9</span></td>        <td align="center"><span class="Bold">n=27</span></td>        <td align="center"><span class="Bold">n=31</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Change from baseline</span></td>        <td align="center">-1.9</td>        <td align="center">0.0</td>        <td align="center">1.3</td>        <td align="center">1.4</td>        <td align="center">0.0</td>        </tr>        <tr>         <td align="left"><span class="Bold">Triglycerides</span></td>        <td align="center"><span class="Bold">n=39</span></td>        <td align="center"><span class="Bold">n=44</span></td>        <td align="center"><span class="Bold">n=11</span></td>        <td align="center"><span class="Bold">n=28</span></td>        <td align="center"><span class="Bold">n=32</span></td>        </tr>        <tr>         <td align="left"><span class="Bold"> Change from baseline</span></td>        <td align="center">-8.9</td>        <td align="center">3.2</td>        <td align="center">17.6</td>        <td align="center">-5.4</td>        <td align="center">3.9</td>        </tr>        <tr>         <td align="left"></td>        <td align="center" colspan="5"><span class="Bold">Proportion of Patients with Shifts</span></td>        </tr>        <tr>         <td align="left"><span class="Bold">Cholesterol</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to High</span></td>        <td align="center">7%</td>        <td align="center">4%</td>        <td align="center">0%</td>        <td align="center">6%</td>        <td align="center">11%</td>        </tr>        <tr>         <td align="left"><span class="Bold">(&lt;170 mg/dL to ≥200 mg/dL)</span></td>        <td align="center">(2/27)</td>        <td align="center">(1/26)</td>        <td align="center">(0/6)</td>        <td align="center">(1/18)</td>        <td align="center">(2/19)</td>        </tr>        <tr>         <td align="left"><span class="Bold">LDL</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to High</span></td>        <td align="center">3%</td>        <td align="center">4%</td>        <td align="center">14%</td>        <td align="center">0%</td>        <td align="center">9%</td>        </tr>        <tr>         <td align="left"><span class="Bold">(&lt;110 mg/dL to ≥130 mg/dL)</span></td>        <td align="center">(1/32)</td>        <td align="center">(1/25)</td>        <td align="center">(1/7)</td>        <td align="center">(0/22)</td>        <td align="center">(2/22)</td>        </tr>        <tr>         <td align="left"><span class="Bold">HDL</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold">Normal to Low</span></td>        <td align="center">14%</td>        <td align="center">7%</td>        <td align="center">29%</td>        <td align="center">13%</td>        <td align="center">23%</td>        </tr>        <tr>         <td align="left"><span class="Bold">( ≥40 mg/dL to &lt;40 mg/dL)</span></td>        <td align="center">(4/28)</td>        <td align="center">(2/30)</td>        <td align="center">(2/7)</td>        <td align="center">(3/23)</td>        <td align="center">(5/22)</td>        </tr>        <tr>         <td align="left"><span class="Bold">Triglycerides</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left"><span class="Bold"> Normal to High</span></td>        <td align="center">3%</td>        <td align="center">5%</td>        <td align="center">13%</td>        <td align="center">8%</td>        <td align="center">7%</td>        </tr>        <tr class="Last">         <td align="left"><span class="Bold">(&lt;150 mg/dL to ≥200 mg/dL)</span></td>        <td align="center">(1/34)</td>        <td align="center">(2/38)</td>        <td align="center">(1/8)</td>        <td align="center">(2/26)</td>        <td align="center">(2/28)</td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.6.3"></a>     <p></p>     <p class="First"> <span class="Underline">Weight Gain</span> </p>     <p>Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-5.6.3.1"></a>      <p></p>      <p class="First">Schizophrenia Trials</p>      <p>Data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of ≥ 7% of body weight from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects are presented in Table 3a.</p>      <div class="scrollingtable">      <table width="90%">        <caption>         <span>Table 3a. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥ 7% Gain in Body Weight from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia</span>        </caption>        <colgroup>        <col align="left" valign="bottom" width="30%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />        </colgroup>       <thead>         <tr class="First">          <th align="left"></th>         <th align="center"></th>         <th class="Botrule" align="center" colspan="4">INVEGA<span class="Sup">&reg;</span></th>         </tr>         <tr>          <th align="left"></th>         <th align="center">Placebo</th>         <th align="center">3 mg/day</th>         <th align="center">6 mg/day</th>         <th align="center">9 mg/day</th>         <th align="center">12 mg/day</th>         </tr>         <tr class="Last">          <th align="left"></th>         <th align="center">n=323</th>         <th align="center">n=112</th>         <th align="center">n=215</th>         <th align="center">n=235</th>         <th align="center">n=218</th>         </tr>        </thead>        <tbody>         <tr class="First">          <td align="left"><span class="Bold">Weight (kg)<br />Change from baseline</span></td>         <td align="center">-0.4</td>         <td align="center">0.6</td>         <td align="center">0.6</td>         <td align="center">1.0</td>         <td align="center">1.1</td>         </tr>         <tr class="Last">          <td align="left"><span class="Bold">Weight Gain<br />≥ 7% increase from baseline</span></td>         <td align="center">5%</td>         <td align="center">7%</td>         <td align="center">6%</td>         <td align="center">9%</td>         <td align="center">9%</td>         </tr>        </tbody>       </table>     </div>      <p>In the uncontrolled, longer-term open-label extension studies, INVEGA<span class="Sup">&reg;</span> was associated with a mean change in weight of +1.4 kg at Week 24 (n=63) and +2.6 kg at Week 52 (n=302).</p>      <p>Weight gain in adolescent subjects with schizophrenia was assessed in a 6-week, double-blind, placebo-controlled study and an open-label extension with a median duration of exposure to INVEGA<span class="Sup">&reg;</span> of 182 days. Data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of ≥ 7% of body weight <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span> from the placebo-controlled 6-week study in adolescent subjects (12–17 years of age) are presented in Table 3b.</p>      <div class="scrollingtable">      <table width="90%">        <caption>         <span>Table 3b. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥ 7% Gain in Body Weight from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia</span>        </caption>        <colgroup>        <col align="left" valign="bottom" width="30%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />         <col align="center" valign="bottom" width="14%" />        </colgroup>       <thead>         <tr class="First">          <th align="left"></th>         <th align="center"></th>         <th class="Botrule" align="center" colspan="4">INVEGA<span class="Sup">&reg;</span></th>         </tr>         <tr>          <th align="left"></th>         <th align="center">Placebo</th>         <th align="center">1.5 mg/day</th>         <th align="center">3 mg/day</th>         <th align="center">6 mg/day</th>         <th align="center">12 mg/day</th>         </tr>         <tr class="Last">          <th align="left"></th>         <th align="center">n=51</th>         <th align="center">n=54</th>         <th align="center">n=16</th>         <th align="center">n=45</th>         <th align="center">n=34</th>         </tr>        </thead>        <tbody>         <tr class="First">          <td align="left"><span class="Bold">Weight (kg)<br />Change from baseline</span></td>         <td align="center">0.0</td>         <td align="center">0.3</td>         <td align="center">0.8</td>         <td align="center">1.2</td>         <td align="center">1.5</td>         </tr>         <tr class="Last">          <td align="left"><span class="Bold">Weight Gain<br />≥ 7% increase from baseline</span></td>         <td align="center">2%</td>         <td align="center">6%</td>         <td align="center">19%</td>         <td align="center">7%</td>         <td align="center">18%</td>         </tr>        </tbody>       </table>     </div>      <p>In the open-label long-term study the proportion of total subjects treated with INVEGA<span class="Sup">&reg;</span> with an increase in body weight of ≥ 7% from baseline was 33%. When treating adolescent patients with INVEGA<span class="Sup">&reg;</span>, weight gain should be assessed against that expected with normal growth. When taking into consideration the median duration of exposure to INVEGA<span class="Sup">&reg;</span> in the open-label study (182 days) along with expected normal growth in this population based on age and gender, an assessment of standardized scores relative to normative data provides a more clinically relevant measure of changes in weight. The mean change from open-label baseline to endpoint in standardized score for weight was 0.1 (4% above the median for normative data). Based on comparison to the normative data, these changes are not considered to be clinically significant.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-5.6.3.2"></a>      <p></p>      <p class="First">Schizoaffective Disorder Trials</p>      <p>In the pooled data from the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder, a higher percentage of INVEGA<span class="Sup">&reg;</span>-treated subjects (5%) had an increase in body weight of ≥ 7% compared with placebo-treated subjects (1%). In the study that examined high- and low-dose groups, the increase in body weight of ≥ 7% was 3% in the low-dose group, 7% in the high-dose group, and 1% in the placebo group.</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.7"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Hyperprolactinemia</h2>    <p class="First">Like other drugs that antagonize dopamine D<span class="Sub">2</span> receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.</p>    <p>Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.</p>    <p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.8"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Potential for Gastrointestinal Obstruction</h2>    <p class="First">Because the INVEGA<span class="Sup">&reg;</span> tablet is non-deformable and does not appreciably change in shape in the gastrointestinal tract, INVEGA<span class="Sup">&reg;</span> should ordinarily not be administered to patients with pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic, for example: esophageal motility disorders, small bowel inflammatory disease, &quot;short gut&quot; syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel's diverticulum). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of drugs in non-deformable controlled-release formulations. Because of the controlled-release design of the tablet, INVEGA<span class="Sup">&reg;</span> should only be used in patients who are able to swallow the tablet whole <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S17.8">Patient Counseling Information (17.8)</a>]</span>.</p>    <p>A decrease in transit time, e.g., as seen with diarrhea, would be expected to decrease bioavailability and an increase in transit time, e.g., as seen with gastrointestinal neuropathy, diabetic gastroparesis, or other causes, would be expected to increase bioavailability. These changes in bioavailability are more likely when the changes in transit time occur in the upper GI tract.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.9"></a>   <a name="section-5.9"></a>    <p></p>    <h2>5.9 Orthostatic Hypotension and Syncope</h2>    <p class="First">Paliperidone can induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. In pooled results of the three placebo-controlled, 6-week, fixed-dose trials in subjects with schizophrenia, syncope was reported in 0.8% (7/850) of subjects treated with INVEGA<span class="Sup">&reg;</span> (3 mg, 6 mg, 9 mg, 12 mg) compared to 0.3% (1/355) of subjects treated with placebo. INVEGA<span class="Sup">&reg;</span> should be used with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.10"></a>   <a name="section-5.10"></a>    <p></p>    <h2>5.10 Leukopenia, Neutropenia, and Agranulocytosis</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.10.1"></a>     <p></p>     <p class="First"> <span class="Italics">Class Effect: </span>In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including INVEGA<span class="Sup">&reg;</span>. Agranulocytosis has also been reported.</p>     <p>Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of INVEGA<span class="Sup">&reg;</span> should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p>     <p>Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt;1000/mm<span class="Sup">3</span>) should discontinue INVEGA<span class="Sup">&reg;</span> and have their WBC followed until recovery.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.11"></a>   <a name="section-5.11"></a>    <p></p>    <h2>5.11 Potential for Cognitive and Motor Impairment</h2>    <p class="First">Somnolence was reported in subjects treated with INVEGA<span class="Sup">&reg;</span><span class="Italics"> [see <a href="#S6.1">Adverse Reactions (6.1</a>, <a href="#S6.2">6.2</a>)]</span>. Antipsychotics, including INVEGA<span class="Sup">&reg;</span>, have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that paliperidone therapy does not adversely affect them.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.12"></a>   <a name="section-5.12"></a>    <p></p>    <h2>5.12 Seizures</h2>    <p class="First">During premarketing clinical trials in subjects with schizophrenia (the three placebo-controlled, 6-week, fixed-dose studies and a study conducted in elderly schizophrenic subjects), seizures occurred in 0.22% of subjects treated with INVEGA<span class="Sup">&reg;</span> (3 mg, 6 mg, 9 mg, 12 mg) and 0.25% of subjects treated with placebo. Like other antipsychotic drugs, INVEGA<span class="Sup">&reg; </span>should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.13"></a>   <a name="section-5.13"></a>    <p></p>    <h2>5.13 Dysphagia</h2>    <p class="First">Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. INVEGA<span class="Sup">&reg;</span> and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.14"></a>   <a name="section-5.14"></a>    <p></p>    <h2>5.14 Suicide</h2>    <p class="First">The possibility of suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for INVEGA<span class="Sup">&reg;</span> should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.15"></a>   <a name="section-5.15"></a>    <p></p>    <h2>5.15 Priapism</h2>    <p class="First">Drugs with alpha-adrenergic blocking effects have been reported to induce priapism. Priapism has been reported with INVEGA<span class="Sup">&reg;</span> during postmarketing surveillance. Severe priapism may require surgical intervention.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.16"></a>   <a name="section-5.16"></a>    <p></p>    <h2>5.16 Thrombotic Thrombocytopenic Purpura (TTP)</h2>    <p class="First">No cases of TTP were observed during clinical studies with paliperidone. Although cases of TTP have been reported in association with risperidone administration, the relationship to risperidone therapy is unknown.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.17"></a>   <a name="section-5.17"></a>    <p></p>    <h2>5.17 Body Temperature Regulation</h2>    <p class="First">Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing INVEGA<span class="Sup">&reg;</span> to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.18"></a>   <a name="section-5.18"></a>    <p></p>    <h2>5.18 Antiemetic Effect</h2>    <p class="First">An antiemetic effect was observed in preclinical studies with paliperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye's syndrome, and brain tumor.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.19"></a>   <a name="section-5.19"></a>    <p></p>    <h2>5.19 Use in Patients with Concomitant Illness</h2>    <p class="First">Clinical experience with INVEGA<span class="Sup">&reg;</span> in patients with certain concomitant illnesses is limited <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.</p>    <p>INVEGA<span class="Sup">&reg;</span> has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical trials. Because of the risk of orthostatic hypotension with INVEGA<span class="Sup">&reg;</span>, caution should be observed in patients with known cardiovascular disease <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.20"></a>   <a name="section-5.20"></a>    <p></p>    <h2>5.20 Monitoring: Laboratory Tests</h2>    <p class="First">No specific laboratory tests are recommended.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="S6"></a>  <a name="section-6"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S6.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Overall Adverse Reaction Profile</h2>    <p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>    <ul>     <li>Increased mortality in elderly patients with dementia-related psychosis <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span> </li>     <li>Cerebrovascular adverse reactions, including stroke, in elderly patients with dementia-related psychosis <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span> </li>     <li>Neuroleptic malignant syndrome <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span> </li>     <li>QT prolongation <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span> </li>     <li>Tardive dyskinesia <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span> </li>     <li>Metabolic changes <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span> </li>     <li>Hyperprolactinemia <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span> </li>     <li>Potential for gastrointestinal obstruction <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span> </li>     <li>Orthostatic hypotension and syncope <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span> </li>     <li>Leukopenia, neutropenia, and agranulocytosis<span class="Italics"> [see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span> </li>     <li>Potential for cognitive and motor impairment <span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span> </li>     <li>Seizures <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span> </li>     <li>Dysphagia <span class="Italics">[see <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span> </li>     <li>Suicide <span class="Italics">[see <a href="#S5.14">Warnings and Precautions (5.14)</a>]</span> </li>     <li>Priapism <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span> </li>     <li>Thrombotic thrombocytopenic purpura (TTP) <span class="Italics">[see <a href="#S5.16">Warnings and Precautions (5.16)</a>]</span> </li>     <li>Disruption of body temperature regulation <span class="Italics">[see <a href="#S5.17">Warnings and Precautions (5.17)</a>]</span> </li>     <li>Antiemetic effect <span class="Italics">[see <a href="#S5.18">Warnings and Precautions (5.18)</a>]</span> </li>     <li>Increased sensitivity in patients with Parkinson's disease or those with dementia with Lewy bodies <span class="Italics">[see <a href="#S5.19">Warnings and Precautions (5.19)</a>]</span> </li>     <li>Diseases or conditions that could affect metabolism or hemodynamic responses <span class="Italics">[see <a href="#S5.19">Warnings and Precautions (5.19)</a>]</span> </li>    </ul>    <p>The most common adverse reactions in clinical trials in adult subjects with schizophrenia (reported in 5% or more of subjects treated with INVEGA<span class="Sup">&reg;</span> and at least twice the placebo rate in any of the dose groups) were extrapyramidal symptoms, tachycardia, and akathisia. The most common adverse reactions in clinical trials in adult patients with schizoaffective disorder (reported in 5% or more of subjects treated with INVEGA<span class="Sup">&reg;</span> and at least twice the placebo rate) were extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis.</p>    <p>The most common adverse reactions that were associated with discontinuation from clinical trials in adult subjects with schizophrenia (causing discontinuation in 2% of INVEGA<span class="Sup">&reg;</span>-treated subjects) were nervous system disorders. The most common adverse reactions that were associated with discontinuation from clinical trials in adult subjects with schizoaffective disorder were gastrointestinal disorders, which resulted in discontinuation in 1% of INVEGA<span class="Sup">&reg;</span>-treated subjects. <span class="Italics">[See <a href="#S6.4">Adverse Reactions (6.4)</a>]</span>.</p>    <p>The safety of INVEGA<span class="Sup">&reg;</span> was evaluated in 1205 adult subjects with schizophrenia who participated in three placebo-controlled, 6-week, double-blind trials, of whom 850 subjects received INVEGA<span class="Sup">&reg;</span> at fixed doses ranging from 3 mg to 12 mg once daily. The information presented in this section was derived from pooled data from these three trials. Additional safety information from the placebo-controlled phase of the long-term maintenance study, in which subjects received INVEGA<span class="Sup">&reg;</span> at daily doses within the range of 3 mg to 15 mg (n=104), is also included.</p>    <p>The safety of INVEGA<span class="Sup">&reg;</span> was evaluated in 150 adolescent subjects 12–17 years of age with schizophrenia who received INVEGA<span class="Sup">&reg;</span> in the dose range of 1.5 mg to 12 mg/day in a 6-week, double-blind, placebo-controlled trial.</p>    <p>The safety of INVEGA<span class="Sup">&reg;</span> was also evaluated in 622 adult subjects with schizoaffective disorder who participated in two placebo-controlled, 6-week, double-blind trials. In one of these trials, 206 subjects were assigned to one of two dose levels of INVEGA<span class="Sup">&reg;</span>: 6 mg with the option to reduce to 3 mg (n = 108) or 12 mg with the option to reduce to 9 mg (n = 98) once daily. In the other study, 214 subjects received flexible doses of INVEGA<span class="Sup">&reg;</span> (3–12 mg once daily). Both studies included subjects who received INVEGA<span class="Sup">&reg;</span> either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.</p>    <p>Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of INVEGA<span class="Sup">&reg;</span> (adverse drug reactions) based on the comprehensive assessment of the available adverse event information. A causal association for INVEGA<span class="Sup">&reg;</span> often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizophrenia in Adults and Adolescents</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.2.1"></a>     <p></p>     <p class="First">Adult Patients with Schizophrenia</p>     <p> <span class="Italics">Table 4</span> enumerates the pooled incidences of adverse reactions reported in the three placebo-controlled, 6-week, fixed-dose studies in adults, listing those that occurred in 2% or more of subjects treated with INVEGA<span class="Sup">&reg;</span> in any of the dose groups, and for which the incidence in INVEGA<span class="Sup">&reg;</span>-treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo.</p>     <div class="scrollingtable">     <table width="85%">       <caption>        <span>Table 4. Adverse Reactions Reported by ≥ 2% of INVEGA<span class="Sup">&reg;</span>-Treated Adult Subjects with Schizophrenia in Three Short-Term, Fixed-Dose, Placebo-Controlled Clinical Trials <a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a></span>       </caption>       <colgroup>       <col align="left" valign="top" width="30%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />       </colgroup>      <thead>        <tr class="First">         <th align="left"></th>        <th align="center" colspan="5"> Percentage of Patients </th>        </tr>        <tr>         <th align="left"></th>        <th align="center"></th>        <th align="center" colspan="4"> INVEGA<span class="Sup">&reg;</span></th>        </tr>        <tr>         <th align="left"></th>        <th align="center" valign="top">Placebo</th>        <th align="center">3 mg once daily</th>        <th align="center">6 mg once daily</th>        <th align="center">9 mg once daily</th>        <th align="center">12 mg once daily</th>        </tr>        <tr>         <th align="left">Body System or Organ Class</th>        <th align="center">(N=355)</th>        <th align="center">(N=127)</th>        <th align="center">(N=235)</th>        <th align="center">(N=246)</th>        <th align="center">(N=242)</th>        </tr>        <tr class="Last">         <th align="left">&nbsp;&nbsp;Dictionary-Derived Term</th>        <th align="center"></th>        <th align="center"></th>        <th align="center"></th>        <th align="center"></th>        <th align="center"></th>        </tr>       </thead>       <tfoot>        <tr>         <td align="left" colspan="6">          <dl class="Footnote">           <dt>            <a href="#footnote-reference-1" name="footnote-1">*</a>           </dt>           <dd>            Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA           <span class="Sup">&reg;</span> dose groups and which occurred at greater incidence than in the placebo group. Data are pooled from three studies; one study included once-daily INVEGA           <span class="Sup">&reg;</span> doses of 3 mg and 9 mg, the second study included 6 mg, 9 mg, and 12 mg, and the third study included 6 mg and 12 mg            <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. Extrapyramidal symptoms includes the terms dyskinesia, dystonia, extrapyramidal disorder, hypertonia, muscle rigidity, oculogyration, parkinsonism, and tremor. Somnolence includes the terms sedation and somnolence. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased. Adverse reactions for which the INVEGA           <span class="Sup">&reg;</span> incidence was equal to or less than placebo are not listed in the table, but included the following: vomiting.          </dd>          </dl> </td>        </tr>       </tfoot>       <tbody>        <tr class="First">         <td align="left"><span class="Bold">Total percentage of subjects with adverse reactions</span></td>        <td align="center">37</td>        <td align="center">48</td>        <td align="center">47</td>        <td align="center">53</td>        <td align="center">59</td>        </tr>        <tr>         <td align="left"><span class="Bold"> <br />Cardiac disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Atrioventricular block first degree</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">1</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Bundle branch block</td>        <td align="center">2</td>        <td align="center">3</td>        <td align="center">1</td>        <td align="center">3</td>        <td align="center">&lt;1</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Sinus arrhythmia</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">1</td>        <td align="center">1</td>        <td align="center">&lt;1</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Tachycardia</td>        <td align="center">7</td>        <td align="center">14</td>        <td align="center">12</td>        <td align="center">12</td>        <td align="center">14</td>        </tr>        <tr>         <td align="left"><span class="Bold"> <br />Gastrointestinal disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Abdominal pain upper</td>        <td align="center">1</td>        <td align="center">1</td>        <td align="center">3</td>        <td align="center">2</td>        <td align="center">2</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Dry mouth</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">3</td>        <td align="center">1</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Salivary hypersecretion</td>        <td align="center">&lt;1</td>        <td align="center">0</td>        <td align="center">&lt;1</td>        <td align="center">1</td>        <td align="center">4</td>        </tr>        <tr>         <td align="left"><span class="Bold"> <br />General disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Asthenia</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">&lt;1</td>        <td align="center">2</td>        <td align="center">2</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Fatigue</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">2</td>        </tr>        <tr>         <td align="left"><span class="Bold"> <br />Nervous system disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Akathisia</td>        <td align="center">4</td>        <td align="center">4</td>        <td align="center">3</td>        <td align="center">8</td>        <td align="center">10</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Dizziness</td>        <td align="center">4</td>        <td align="center">6</td>        <td align="center">5</td>        <td align="center">4</td>        <td align="center">5</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Extrapyramidal symptoms</td>        <td align="center">8</td>        <td align="center">10</td>        <td align="center">7</td>        <td align="center">20</td>        <td align="center">18</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Headache</td>        <td align="center">12</td>        <td align="center">11</td>        <td align="center">12</td>        <td align="center">14</td>        <td align="center">14</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Somnolence</td>        <td align="center">7</td>        <td align="center">6</td>        <td align="center">9</td>        <td align="center">10</td>        <td align="center">11</td>        </tr>        <tr>         <td align="left"><span class="Bold"> <br />Vascular disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr class="Last">         <td align="left">&nbsp;&nbsp;Orthostatic hypotension</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">1</td>        <td align="center">2</td>        <td align="center">4</td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.2.2"></a>     <p></p>     <p class="First">Adolescent Patients with Schizophrenia</p>     <p> <span class="Italics">Table 5</span> lists the adverse reactions reported in a fixed-dose, placebo-controlled study in adolescent subjects 12–17 years of age with schizophrenia, listing those that occurred in 2% or more of subjects treated with INVEGA<span class="Sup">&reg;</span> in any of the dose groups, and for which the incidence in INVEGA<span class="Sup">&reg;</span>-treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo.</p>     <div class="scrollingtable">     <table width="85%">       <caption>        <span>Table 5. Adverse Reactions Reported by ≥ 2% of INVEGA<span class="Sup">&reg;</span>-Treated Adolescent Subjects with Schizophrenia in a Fixed-Dose, Placebo-Controlled Clinical Trial <a class="Sup" href="#footnote-2" name="footnote-reference-2">*</a></span>       </caption>       <colgroup>       <col align="left" valign="top" width="30%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />        <col align="center" valign="top" width="14%" />       </colgroup>      <thead>        <tr class="First">         <th align="left"></th>        <th align="center" colspan="5">Percentage of Patients</th>        </tr>        <tr>         <th align="left"></th>        <th align="center"></th>        <th align="center" colspan="4">INVEGA<span class="Sup">&reg;</span></th>        </tr>        <tr>         <th align="left"></th>        <th align="center">Placebo</th>        <th align="center">1.5 mg once daily</th>        <th align="center">3 mg once daily</th>        <th align="center">6 mg once daily</th>        <th align="center">12 mg once daily</th>        </tr>        <tr>         <th align="left">Body System or Organ Class</th>        <th align="center">(N=51)</th>        <th align="center">(N=54)</th>        <th align="center">(N=16)</th>        <th align="center">(N=45)</th>        <th align="center">(N=35)</th>        </tr>        <tr class="Last">         <th align="left">&nbsp;&nbsp;Dictionary-Derived Term</th>        <th align="center"></th>        <th align="center"></th>        <th align="center"></th>        <th align="center"></th>        <th align="center"></th>        </tr>       </thead>       <tfoot>        <tr>         <td align="left" colspan="6">          <dl class="Footnote">           <dt>            <a href="#footnote-reference-2" name="footnote-2">*</a>           </dt>           <dd>            Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA           <span class="Sup">&reg;</span> dose groups and which occurred at greater incidence than in the placebo group. Extrapyramidal symptoms includes the terms oculogyric crisis, muscle rigidity, musculoskeletal stiffness, nuchal rigidity, torticollis, trismus, bradykinesia, cogwheel rigidity, dyskinesia, dystonia, extrapyramidal disorder, hypertonia, hypokinesia, muscle contractions involuntary, parkinsonian gait, parkinsonism, tremor, and restlessness. Somnolence includes the terms somnolence, sedation, and hypersomnia. Insomnia includes the terms insomnia and initial insomnia. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased. Hypertension includes the terms hypertension and blood pressure increased. Gynecomastia includes the terms gynecomastia and breast swelling.          </dd>          </dl> </td>        </tr>       </tfoot>       <tbody>        <tr class="First">         <td align="left"><span class="Bold">Total percentage of subjects with adverse reactions</span></td>        <td align="center">43</td>        <td align="center">37</td>        <td align="center">50</td>        <td align="center">58</td>        <td align="center">74</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">Cardiac disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Tachycardia</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">6</td>        <td align="center">9</td>        <td align="center">6</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">Eye disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Vision blurred</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">Gastrointestinal disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Dry mouth</td>        <td align="center">2</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Salivary hypersecretion</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">6</td>        <td align="center">2</td>        <td align="center">0</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Swollen tongue</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Vomiting</td>        <td align="center">10</td>        <td align="center">0</td>        <td align="center">6</td>        <td align="center">11</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">General disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Asthenia</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Fatigue</td>        <td align="center">0</td>        <td align="center">4</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left" colspan="2"> <br /> <span class="Bold">Infections and infestations</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Nasopharyngitis</td>        <td align="center">2</td>        <td align="center">4</td>        <td align="center">0</td>        <td align="center">4</td>        <td align="center">0</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">Investigations</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Weight increased</td>        <td align="center">0</td>        <td align="center">7</td>        <td align="center">6</td>        <td align="center">2</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">Nervous system disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Akathisia</td>        <td align="center">0</td>        <td align="center">4</td>        <td align="center">6</td>        <td align="center">11</td>        <td align="center">17</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Dizziness</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">6</td>        <td align="center">2</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Extrapyramidal symptoms</td>        <td align="center">0</td>        <td align="center">4</td>        <td align="center">19</td>        <td align="center">18</td>        <td align="center">23</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Headache</td>        <td align="center">4</td>        <td align="center">9</td>        <td align="center">6</td>        <td align="center">4</td>        <td align="center">14</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Lethargy</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Somnolence</td>        <td align="center">4</td>        <td align="center">9</td>        <td align="center">13</td>        <td align="center">20</td>        <td align="center">26</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Tongue paralysis</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left"> <br /> <span class="Bold">Psychiatric disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Anxiety</td>        <td align="center">4</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">9</td>        </tr>        <tr>         <td align="left" colspan="3"> <br /> <span class="Bold">Reproductive system and breast disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Amenorrhea</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">6</td>        <td align="center">0</td>        <td align="center">0</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Galactorrhea</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">4</td>        <td align="center">0</td>        </tr>        <tr>         <td align="left">&nbsp;&nbsp;Gynecomastia</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">3</td>        </tr>        <tr>         <td align="left" colspan="3"> <br /> <span class="Bold">Respiratory, thoracic and mediastinal disorders</span></td>        <td align="center"></td>        <td align="center"></td>        <td align="center"></td>        </tr>        <tr class="Last">         <td align="left">&nbsp;&nbsp;Epistaxis</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">0</td>        <td align="center">2</td>        <td align="center">0</td>        </tr>       </tbody>      </table>    </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.3"></a>   <a name="section-6.3"></a>    <p></p>    <h2>6.3 Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizoaffective Disorder in Adults</h2>    <p class="First"> <span class="Italics">Table 6</span> enumerates the pooled incidences of adverse reactions reported in the two placebo-controlled 6-week studies in adult subjects, listing those that occurred in 2% or more of subjects treated with INVEGA<span class="Sup">&reg;</span> and for which the incidence in INVEGA<span class="Sup">&reg;</span>-treated subjects was greater than the incidence in subjects treated with placebo.</p>    <div class="scrollingtable">    <table width="85%">      <caption>       <span>Table 6. Adverse Drug Reactions Reported by ≥ 2% of INVEGA<span class="Sup">&reg;</span>-Treated Adult Subjects with Schizoaffective Disorder in Two Double-Blind, Placebo-Controlled Clinical Trials <a class="Sup" href="#footnote-3" name="footnote-reference-3">*</a></span>      </caption>      <colgroup>      <col align="left" valign="top" width="40%" />       <col align="center" valign="top" width="15%" />       <col align="center" valign="top" width="15%" />       <col align="center" valign="top" width="15%" />       <col align="center" valign="top" width="15%" />      </colgroup>     <thead>       <tr class="First">        <th align="left"></th>       <th align="center" colspan="4"> Percentage of Patients </th>       </tr>       <tr>        <th align="left"></th>       <th align="center"></th>       <th align="center">INVEGA<span class="Sup">&reg;</span></th>       <th align="center">INVEGA<span class="Sup">&reg;</span></th>       <th align="center">INVEGA<span class="Sup">&reg;</span></th>       </tr>       <tr>        <th align="left"></th>       <th align="center">Placebo</th>       <th align="center">3–6 mg once-daily fixed-dose range</th>       <th align="center">9–12 mg once-daily fixed-dose range</th>       <th align="center">3–12 mg once-daily flexible dose</th>       </tr>       <tr>        <th align="left">Body System or Organ Class</th>       <th align="center">(N=202)</th>       <th align="center">(N=108)</th>       <th align="center">(N=98)</th>       <th align="center">(N=214)</th>       </tr>       <tr class="Last">        <th align="left">&nbsp;&nbsp;Dictionary-Derived Term</th>       <th align="center"></th>       <th align="center"></th>       <th align="center"></th>       <th align="center"></th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="5">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-3" name="footnote-3">*</a>          </dt>          <dd>          Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA          <span class="Sup">&reg;</span> dose groups and which occurred at greater incidence than in the placebo group. Data are pooled from two studies. One study included once-daily INVEGA          <span class="Sup">&reg;</span> doses of 6 mg (with the option to reduce to 3 mg) and 12 mg (with the option to reduce to 9 mg). The second study included flexible once-daily doses of 3 to 12 mg. Among the 420 subjects treated with INVEGA          <span class="Sup">&reg;</span>, 230 (55%) received INVEGA          <span class="Sup">&reg;</span> as monotherapy and 190 (45%) received INVEGA          <span class="Sup">&reg; </span>as an adjunct to mood stabilizers and/or antidepressants. Extrapyramidal symptoms includes the terms bradykinesia, drooling, dyskinesia, dystonia, hypertonia, muscle rigidity, muscle twitching, oculogyration, parkinsonian gait, parkinsonism, restlessness, and tremor. Somnolence includes the terms sedation and somnolence. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased.         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td align="left"><span class="Bold">Total percentage of subjects with adverse reactions</span></td>       <td align="center">32</td>       <td align="center">48</td>       <td align="center">50</td>       <td align="center">43</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Cardiac disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Tachycardia</td>       <td align="center">2</td>       <td align="center">3</td>       <td align="center">1</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Gastrointestinal disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Abdominal discomfort/Abdominal pain upper</td>       <td align="center">1</td>       <td align="center">1</td>       <td align="center">0</td>       <td align="center">3</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Constipation</td>       <td align="center">2</td>       <td align="center">4</td>       <td align="center">5</td>       <td align="center">4</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Dyspepsia</td>       <td align="center">2</td>       <td align="center">5</td>       <td align="center">6</td>       <td align="center">6</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Nausea</td>       <td align="center">6</td>       <td align="center">8</td>       <td align="center">8</td>       <td align="center">5</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Stomach discomfort</td>       <td align="center">1</td>       <td align="center">0</td>       <td align="center">1</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />General disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Asthenia</td>       <td align="center">1</td>       <td align="center">3</td>       <td align="center">4</td>       <td align="center">&lt;1</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Infections and Infestations</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Nasopharyngitis</td>       <td align="center">1</td>       <td align="center">2</td>       <td align="center">5</td>       <td align="center">3</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Rhinitis</td>       <td align="center">0</td>       <td align="center">1</td>       <td align="center">3</td>       <td align="center">1</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Upper respiratory tract infection</td>       <td align="center">1</td>       <td align="center">2</td>       <td align="center">2</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Investigations</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Weight increased</td>       <td align="center">1</td>       <td align="center">5</td>       <td align="center">4</td>       <td align="center">4</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Metabolism and nutrition disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Decreased appetite</td>       <td align="center">&lt;1</td>       <td align="center">1</td>       <td align="center">0</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Increased appetite</td>       <td align="center">&lt;1</td>       <td align="center">3</td>       <td align="center">2</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Musculoskeletal and connective tissue disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Back pain</td>       <td align="center">1</td>       <td align="center">1</td>       <td align="center">1</td>       <td align="center">3</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Myalgia</td>       <td align="center">&lt;1</td>       <td align="center">2</td>       <td align="center">4</td>       <td align="center">1</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Nervous system disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Akathisia</td>       <td align="center">4</td>       <td align="center">4</td>       <td align="center">6</td>       <td align="center">6</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Dysarthria</td>       <td align="center">0</td>       <td align="center">1</td>       <td align="center">4</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Extrapyramidal symptoms</td>       <td align="center">8</td>       <td align="center">20</td>       <td align="center">17</td>       <td align="center">12</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Somnolence</td>       <td align="center">5</td>       <td align="center">12</td>       <td align="center">12</td>       <td align="center">8</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Psychiatric disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Sleep disorder</td>       <td align="center">&lt;1</td>       <td align="center">2</td>       <td align="center">3</td>       <td align="center">0</td>       </tr>       <tr>        <td align="left"><span class="Bold"> <br />Respiratory, thoracic and mediastinal disorders</span></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       <td align="center"></td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Cough</td>       <td align="center">1</td>       <td align="center">1</td>       <td align="center">3</td>       <td align="center">1</td>       </tr>       <tr class="Last">        <td align="left">&nbsp;&nbsp;Pharyngolaryngeal pain</td>       <td align="center">&lt;1</td>       <td align="center">0</td>       <td align="center">2</td>       <td align="center">1</td>       </tr>      </tbody>     </table>   </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.3.1"></a>     <p></p>     <p class="First">Monotherapy versus Adjunctive Therapy</p>     <p>The designs of the two placebo-controlled, 6-week, double-blind trials in adult subjects with schizoaffective disorder included the option for subjects to receive antidepressants (except monoamine oxidase inhibitors) and/or mood stabilizers (lithium, valproate, or lamotrigine). In the subject population evaluated for safety, 230 (55%) subjects received INVEGA<span class="Sup">&reg;</span> as monotherapy and 190 (45%) subjects received INVEGA<span class="Sup">&reg;</span> as an adjunct to mood stabilizers and/or antidepressants. When comparing these 2 subpopulations, only nausea occurred at a greater frequency (≥ 3% difference) in subjects receiving INVEGA<span class="Sup">&reg;</span> as monotherapy.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.4"></a>   <a name="section-6.4"></a>    <p></p>    <h2>6.4 Discontinuations Due to Adverse Reactions</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.4.1"></a>     <p></p>     <p class="First">Schizophrenia Trials</p>     <p>The percentages of subjects who discontinued due to adverse reactions in the three schizophrenia placebo-controlled, 6-week, fixed-dose studies in adults were 3% and 1% in INVEGA<span class="Sup">&reg;</span>- and placebo-treated subjects, respectively. The most common reasons for discontinuation were nervous system disorders (2% and 0% in INVEGA<span class="Sup">&reg;</span>- and placebo-treated subjects, respectively).</p>     <p>Among the adverse reactions in the 6-week, fixed-dose, placebo-controlled study in adolescents with schizophrenia, only dystonia led to discontinuation (&lt;1% of INVEGA<span class="Sup">&reg;</span>-treated subjects).</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.4.2"></a>     <p></p>     <p class="First">Schizoaffective Disorder Trials</p>     <p>The percentages of subjects who discontinued due to adverse reactions in the two schizoaffective disorder placebo-controlled 6-week studies in adults were 1% and &lt;1% in INVEGA<span class="Sup">&reg;</span>- and placebo-treated subjects, respectively. The most common reasons for discontinuation were gastrointestinal disorders (1% and 0% in INVEGA<span class="Sup">&reg;</span>- and placebo-treated subjects, respectively).</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.5"></a>   <a name="section-6.5"></a>    <p></p>    <h2>6.5 Dose-Related Adverse Reactions</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.5.1"></a>     <p></p>     <p class="First">Schizophrenia Trials</p>     <p>Based on the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia, among the adverse reactions that occurred with a greater than 2% incidence in the subjects treated with INVEGA<span class="Sup">&reg;</span>, the incidences of the following adverse reactions increased with dose: somnolence, orthostatic hypotension, akathisia, dystonia, extrapyramidal disorder, hypertonia, parkinsonism, and salivary hypersecretion. For most of these, the increased incidence was seen primarily at the 12 mg dose, and, in some cases, the 9 mg dose.</p>     <p>In the 6-week, fixed-dose, placebo-controlled study in adolescents with schizophrenia, among the adverse reactions that occurred with &gt;2% incidence in the subjects treated with INVEGA<span class="Sup">&reg;</span>, the incidences of the following adverse reactions increased with dose: tachycardia, akathisia, extrapyramidal symptoms, somnolence, and headache.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.5.2"></a>     <p></p>     <p class="First">Schizoaffective Disorder Trials</p>     <p>In a placebo-controlled, 6-week, high- and low-dose study in adult subjects with schizoaffective disorder, akathisia, dystonia, dysarthria, myalgia, nasopharyngitis, rhinitis, cough, and pharyngolaryngeal pain occurred more frequently (i.e., a difference of at least 2%) in subjects who received higher doses of INVEGA<span class="Sup">&reg;</span> compared with subjects who received lower doses.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.6"></a>   <a name="section-6.6"></a>    <p></p>    <h2>6.6 Demographic Differences</h2>    <p class="First">An examination of population subgroups in the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia and in the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder did not reveal any evidence of clinically relevant differences in safety on the basis of gender or race alone; there was also no difference on the basis of age <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.7"></a>   <a name="section-6.7"></a>    <p></p>    <h2>6.7 Extrapyramidal Symptoms (EPS)</h2>    <p class="First">Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline) which evaluates akathisia, (3) use of anticholinergic medications to treat emergent EPS (<span class="Italics">Table 7</span>), and (4) incidence of spontaneous reports of EPS (<span class="Italics">Table 8</span>). For the Simpson-Angus Scale, spontaneous EPS reports and use of anticholinergic medications, there was a dose-related increase observed for the 9 mg and 12 mg doses. There was no difference observed between placebo and INVEGA<span class="Sup">&reg; </span>3 mg and 6 mg doses for any of these EPS measures.</p>    <div class="scrollingtable">    <table width="80%">      <caption>       <span>Table 7. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Ratings Scales and Use of Anticholinergic Medication – Schizophrenia Studies in Adults</span>      </caption>      <colgroup>      <col align="left" valign="middle" width="20%" />       <col align="center" valign="middle" width="16%" />       <col align="center" valign="middle" width="16%" />       <col align="center" valign="middle" width="16%" />       <col align="center" valign="middle" width="16%" />       <col align="center" valign="middle" width="16%" />      </colgroup>     <thead>       <tr class="First">        <th align="left"></th>       <th align="center" colspan="5">Percentage of Patients</th>       </tr>       <tr>        <th align="left" colspan="2"></th>       <th align="center" colspan="4" valign="top">INVEGA<span class="Sup">&reg;</span></th>       </tr>       <tr>        <th align="left"></th>       <th align="center" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Placebo </th>       <th align="center">3 mg once daily</th>       <th align="center">6 mg once daily</th>       <th align="center">9 mg once daily</th>       <th align="center">12 mg once daily</th>       </tr>       <tr class="Last">        <th align="left" valign="top">EPS Group</th>       <th align="center" valign="top">(N=355)</th>       <th align="center" valign="top">(N=127)</th>       <th align="center" valign="top">(N=235)</th>       <th align="center" valign="top">(N=246)</th>       <th align="center" valign="top">(N=242)</th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="6">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-4" name="footnote-4">*</a>          </dt>          <dd>           For Parkinsonism, percent of patients with Simpson-Angus global score &gt; 0.3 (Global score defined as total sum of items score divided by the number of items)         </dd>          <dt>           <a href="#footnote-reference-5" name="footnote-5">†</a>          </dt>          <dd>          For Akathisia, percent of patients with Barnes Akathisia Rating Scale global score ≥ 2         </dd>          <dt>           <a href="#footnote-reference-6" name="footnote-6">‡</a>          </dt>          <dd>          Percent of patients who received anticholinergic medications to treat emergent EPS         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td align="left">Parkinsonism<a class="Sup" href="#footnote-4" name="footnote-reference-4">*</a></td>       <td align="center">9</td>       <td align="center">11</td>       <td align="center">3</td>       <td align="center">15</td>       <td align="center">14</td>       </tr>       <tr>        <td align="left">Akathisia<a class="Sup" href="#footnote-5" name="footnote-reference-5">†</a></td>       <td align="center">6</td>       <td align="center">6</td>       <td align="center">4</td>       <td align="center">7</td>       <td align="center">9</td>       </tr>       <tr class="Last">        <td align="left">Use of anticholinergic medications<a class="Sup" href="#footnote-6" name="footnote-reference-6">‡</a></td>       <td align="center">10</td>       <td align="center">10</td>       <td align="center">9</td>       <td align="center">22</td>       <td align="center">22</td>       </tr>      </tbody>     </table>   </div>    <div class="scrollingtable">    <table width="80%">      <caption>       <span>Table 8. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies in Adults</span>      </caption>      <colgroup>      <col align="left" valign="top" width="20%" />       <col align="center" valign="top" width="16%" />       <col align="center" valign="top" width="16%" />       <col align="center" valign="top" width="16%" />       <col align="center" valign="top" width="16%" />       <col align="center" valign="top" width="16%" />      </colgroup>     <thead>       <tr class="First">        <th align="left"></th>       <th align="center" colspan="5">Percentage of Patients</th>       </tr>       <tr>        <th align="left" colspan="2"></th>       <th align="center" colspan="4">INVEGA<span class="Sup">&reg;</span></th>       </tr>       <tr>        <th align="left"></th>       <th align="center">Placebo</th>       <th align="center">3 mg once daily</th>       <th align="center">6 mg once daily</th>       <th align="center">9 mg once daily</th>       <th align="center">12 mg once daily</th>       </tr>       <tr class="Last">        <th align="left">EPS Group</th>       <th align="center">(N=355)</th>       <th align="center">(N=127)</th>       <th align="center">(N=235)</th>       <th align="center">(N=246)</th>       <th align="center">(N=242)</th>       </tr>      </thead>      <tfoot>       <tr class="First">        <td align="left" colspan="6">Dyskinesia group includes: Dyskinesia, extrapyramidal disorder, muscle twitching, tardive dyskinesia</td>       </tr>       <tr>        <td align="left" colspan="6">Dystonia group includes: Dystonia, muscle spasms, oculogyration, trismus</td>       </tr>       <tr>        <td align="left" colspan="6">Hyperkinesia group includes: Akathisia, hyperkinesia</td>       </tr>       <tr>        <td align="left" colspan="6">Parkinsonism group includes: Bradykinesia, cogwheel rigidity, drooling,<br />hypertonia, hypokinesia, muscle rigidity, musculoskeletal stiffness, parkinsonism</td>       </tr>       <tr class="Last">        <td align="left" colspan="6">Tremor group includes: Tremor</td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td align="left">Overall percentage of patients with EPS-related AE</td>       <td align="center">11</td>       <td align="center">13</td>       <td align="center">10</td>       <td align="center">25</td>       <td align="center">26</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Dyskinesia</td>       <td align="center">3</td>       <td align="center">5</td>       <td align="center">3</td>       <td align="center">8</td>       <td align="center">9</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Dystonia</td>       <td align="center">1</td>       <td align="center">1</td>       <td align="center">1</td>       <td align="center">5</td>       <td align="center">5</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Hyperkinesia</td>       <td align="center">4</td>       <td align="center">4</td>       <td align="center">3</td>       <td align="center">8</td>       <td align="center">10</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Parkinsonism</td>       <td align="center">2</td>       <td align="center">3</td>       <td align="center">3</td>       <td align="center">7</td>       <td align="center">6</td>       </tr>       <tr class="Last">        <td align="left">&nbsp;&nbsp;Tremor</td>       <td align="center">3</td>       <td align="center">3</td>       <td align="center">3</td>       <td align="center">4</td>       <td align="center">3</td>       </tr>      </tbody>     </table>   </div>    <p>Compared to data from the studies in adults subjects with schizophrenia, pooled data from the two placebo-controlled 6-week studies in adult subjects with schizoaffective disorder showed similar types and frequencies of EPS as measured by rating scales, anticholinergic medication use, and spontaneous reports of EPS-related adverse events. For subjects with schizoaffective disorder, there was no dose-related increase in EPS observed for parkinsonism with the Simpson-Angus scale or akathisia with the Barnes Akathisia Rating Scale. There was a dose-related increase observed with spontaneous EPS reports of hyperkinesia and dystonia and in the use of anticholinergic medications.</p>    <p> <span class="Italics">Table 9</span> shows the EPS data from the pooled schizoaffective disorder trials.</p>    <div class="scrollingtable">    <table width="80%">      <caption>       <span>Table 9. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizoaffective Disorder Studies in Adults</span>      </caption>      <colgroup>      <col align="left" valign="top" width="40%" />       <col align="center" valign="top" width="15%" />       <col align="center" valign="top" width="15%" />       <col align="center" valign="top" width="15%" />       <col align="center" valign="top" width="15%" />      </colgroup>     <thead>       <tr class="First">        <th align="left"></th>       <th align="center" colspan="4">Percentage of Patients</th>       </tr>       <tr>        <th align="left"></th>       <th align="center"></th>       <th align="center" colspan="3">INVEGA<span class="Sup">&reg;</span></th>       </tr>       <tr>        <th align="left"></th>       <th align="center" valign="middle">Placebo</th>       <th align="center" valign="middle">3–6 mg once-daily fixed-dose range</th>       <th align="center" valign="middle">9–12 mg once-daily fixed-dose range</th>       <th align="center" valign="middle">3–12 mg once-daily flexible dose</th>       </tr>       <tr class="Last">        <th align="left">EPS Group</th>       <th align="center">(N=202)</th>       <th align="center">(N=108)</th>       <th align="center">(N=98)</th>       <th align="center">(N=214)</th>       </tr>      </thead>      <tfoot>       <tr class="First">        <td align="left" colspan="5">Dyskinesia group includes: Dyskinesia, muscle twitching</td>       </tr>       <tr>        <td align="left" colspan="5">Dystonia group includes: Dystonia, muscle spasms, oculogyration</td>       </tr>       <tr>        <td align="left" colspan="5">Hyperkinesia group includes: Akathisia, hyperkinesia, restlessness</td>       </tr>       <tr>        <td align="left" colspan="5">Parkinsonism group includes: Bradykinesia, drooling, hypertonia, muscle rigidity, muscle tightness, musculoskeletal stiffness, parkinsonian gait, parkinsonism</td>       </tr>       <tr class="Last">        <td align="left" colspan="5">Tremor group includes: Tremor</td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td align="left">Overall percentage of patients with EPS-related AE</td>       <td align="center">11</td>       <td align="center">23</td>       <td align="center">22</td>       <td align="center">17</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Dyskinesia</td>       <td align="center">1</td>       <td align="center">3</td>       <td align="center">1</td>       <td align="center">1</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Dystonia</td>       <td align="center">1</td>       <td align="center">2</td>       <td align="center">3</td>       <td align="center">2</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Hyperkinesia</td>       <td align="center">5</td>       <td align="center">5</td>       <td align="center">8</td>       <td align="center">7</td>       </tr>       <tr>        <td align="left">&nbsp;&nbsp;Parkinsonism</td>       <td align="center">3</td>       <td align="center">14</td>       <td align="center">7</td>       <td align="center">7</td>       </tr>       <tr class="Last">        <td align="left">&nbsp;&nbsp;Tremor</td>       <td align="center">3</td>       <td align="center">12</td>       <td align="center">11</td>       <td align="center">5</td>       </tr>      </tbody>     </table>   </div>    <p>The incidences of EPS-related adverse events in the adolescent schizophrenia studies showed a similar dose-related pattern to those in the adult studies. There were notably higher incidences of dystonia, hyperkinesia, tremor, and parkinsonism in the adolescent population as compared to the adult studies <span class="Italics">(Table 10)</span>.</p>    <div class="scrollingtable">    <table width="80%">      <caption>       <span>Table 10. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies in Adolescent Subjects</span>      </caption>      <colgroup>      <col align="left" valign="middle" width="30%" />       <col align="center" valign="middle" width="14%" />       <col align="center" valign="middle" width="14%" />       <col align="center" valign="middle" width="14%" />       <col align="center" valign="middle" width="14%" />       <col align="center" valign="middle" width="14%" />      </colgroup>     <thead>       <tr class="First">        <th align="left"></th>       <th align="center" colspan="5" valign="top">Percentage of Patients</th>       </tr>       <tr>        <th align="left"></th>       <th align="center"></th>       <th align="center" colspan="4" valign="top">INVEGA<span class="Sup">&reg;</span></th>       </tr>       <tr>        <th align="left"></th>       <th align="center" valign="top">Placebo</th>       <th align="center">1.5 mg once daily</th>       <th align="center">3 mg once daily</th>       <th align="center">6 mg once daily</th>       <th align="center">12 mg once daily</th>       </tr>       <tr class="Last">        <th align="left">EPS Group</th>       <th align="center">(N=51)</th>       <th align="center">(N=54)</th>       <th align="center">(N=16)</th>       <th align="center">(N=45)</th>       <th align="center">(N=35)</th>       </tr>      </thead>      <tfoot>       <tr class="First">        <td align="left" colspan="6">Hyperkinesia group includes: Akathisia</td>       </tr>       <tr>        <td align="left" colspan="6">Dystonia group includes: Dystonia, muscle contracture, oculogyric crisis, tongue paralysis, torticollis</td>       </tr>       <tr>        <td align="left" colspan="6">Tremor group includes: Tremor</td>       </tr>       <tr>        <td align="left" colspan="6">Parkinsonism group includes: Cogwheel rigidity, extrapyramidal disorder, muscle rigidity</td>       </tr>       <tr class="Last">        <td align="left" colspan="6">Dyskinesia group includes: Dyskinesia, muscle contractions involuntary</td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td align="left" valign="top">Overall percentage of patients with EPS-related AE</td>       <td align="center" valign="top">0</td>       <td align="center" valign="top">6</td>       <td align="center" valign="top">25</td>       <td align="center" valign="top">22</td>       <td align="center" valign="top">40</td>       </tr>       <tr>        <td align="left">Hyperkinesia</td>       <td align="center">0</td>       <td align="center">4</td>       <td align="center">6</td>       <td align="center">11</td>       <td align="center">17</td>       </tr>       <tr>        <td align="left">Dystonia</td>       <td align="center">0</td>       <td align="center">2</td>       <td align="center">0</td>       <td align="center">11</td>       <td align="center">14</td>       </tr>       <tr>        <td align="left">Tremor</td>       <td align="center">0</td>       <td align="center">2</td>       <td align="center">6</td>       <td align="center">7</td>       <td align="center">11</td>       </tr>       <tr>        <td align="left">Parkinsonism</td>       <td align="center">0</td>       <td align="center">0</td>       <td align="center">6</td>       <td align="center">2</td>       <td align="center">14</td>       </tr>       <tr class="Last">        <td align="left">Dyskinesia</td>       <td align="center">0</td>       <td align="center">2</td>       <td align="center">6</td>       <td align="center">2</td>       <td align="center">6</td>       </tr>      </tbody>     </table>   </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.7.1"></a>     <p></p>     <p class="First">Dystonia</p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-6.7.1.1"></a>      <p></p>      <p class="First"> <span class="Italics">Class Effect: </span>Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.8"></a>   <a name="section-6.8"></a>    <p></p>    <h2>6.8 Laboratory Test Abnormalities</h2>    <p class="First">In the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia and from the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder, between-group comparisons revealed no medically important differences between INVEGA<span class="Sup">&reg;</span> and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA<span class="Sup">&reg;</span> and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA<span class="Sup">&reg;</span> was associated with increases in serum prolactin <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.9"></a>   <a name="section-6.9"></a>    <p></p>    <h2>6.9 Other Adverse Reactions Observed During Premarketing Evaluation of INVEGA<span class="Sup">&reg;</span> </h2>    <p class="First">The following additional adverse reactions occurred in &lt; 2% of INVEGA<span class="Sup">&reg;</span>-treated subjects in the above schizophrenia and schizoaffective disorder clinical trial datasets. The following also includes additional adverse reactions reported at any frequency by INVEGA<span class="Sup">&reg;</span>-treated subjects who participated in other clinical studies.</p>    <p> <span class="Bold">Cardiac disorders:</span> bradycardia, palpitations</p>    <p> <span class="Bold">Eye disorders:</span> eye movement disorder</p>    <p> <span class="Bold">Gastrointestinal disorders:</span> flatulence </p>    <p> <span class="Bold">General disorders:</span> edema</p>    <p> <span class="Bold">Immune system disorders:</span> anaphylactic reaction</p>    <p> <span class="Bold">Infections and infestations:</span> urinary tract infection</p>    <p> <span class="Bold">Investigations: </span>alanine aminotransferase increased, aspartate aminotransferase increased </p>    <p> <span class="Bold">Musculoskeletal and connective tissue disorders:</span> arthralgia, pain in extremity</p>    <p> <span class="Bold">Nervous system disorders:</span> opisthotonus</p>    <p> <span class="Bold">Psychiatric disorders: </span>agitation, insomnia, nightmare</p>    <p> <span class="Bold">Reproductive system and breast disorders:</span> breast discomfort, menstruation irregular, retrograde ejaculation</p>    <p> <span class="Bold">Respiratory, thoracic and mediastinal disorders:</span> nasal congestion</p>    <p> <span class="Bold">Skin and subcutaneous tissue disorders:</span> pruritus, rash</p>    <p> <span class="Bold">Vascular disorders:</span> hypertension </p>    <p>The safety of INVEGA<span class="Sup">&reg;</span> was also evaluated in a long-term trial designed to assess the maintenance of effect with INVEGA<span class="Sup">&reg;</span> in adults with schizophrenia <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. In general, adverse reaction types, frequencies, and severities during the initial 14-week open-label phase of this study were comparable to those observed in the 6-week, placebo-controlled, fixed-dose studies. Adverse reactions reported during the long-term double-blind phase of this study were similar in type and severity to those observed in the initial 14-week open-label phase.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.10"></a>   <a name="section-6.10"></a>    <p></p>    <h2>6.10 Postmarketing Experience</h2>    <p class="First">The following adverse reactions have been identified during postapproval use of INVEGA<span class="Sup">&reg;</span>; because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency: angioedema, ileus, priapism, swollen tongue, tardive dyskinesia, urinary incontinence, urinary retention.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.11"></a>   <a name="section-6.11"></a>    <p></p>    <h2>6.11 Adverse Reactions Reported With Risperidone</h2>    <p class="First">Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with risperidone can be found in the ADVERSE REACTIONS section of the risperidone package insert.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="S7"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S7.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Potential for INVEGA<span class="Sup">&reg;</span> to Affect Other Drugs</h2>    <p class="First">Given the primary CNS effects of paliperidone <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1</a>, <a href="#S6.2">6.2</a>)]</span>, INVEGA<span class="Sup">&reg;</span> should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopamine agonists.</p>    <p>Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA<span class="Sup">&reg;</span> is administered with other therapeutic agents that have this potential <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>    <p>Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. <span class="Italics">In vitro</span> studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.</p>    <p>Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No <span class="Italics">in vivo</span> data are available and the clinical relevance is unknown.</p>    <p>Pharmacokinetic interaction between lithium and INVEGA<span class="Sup">&reg;</span> is unlikely.</p>    <p>In a drug interaction study, co-administration of INVEGA<span class="Sup">&reg;</span> (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC<span class="Sub">24h</span> and C<span class="Sub">max,ss</span>) of valproate in 13 patients stabilized on valproate. In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when INVEGA<span class="Sup">&reg;</span> 3–15 mg/day was added to their existing valproate treatment.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Potential for Other Drugs to Affect INVEGA<span class="Sup">&reg;</span> </h2>    <p class="First">Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While <span class="Italics">in vitro</span> studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, <span class="Italics">in vivo</span> studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance.<span class="Italics"> In vitro</span> studies have shown that paliperidone is a P-gp substrate.</p>    <p>Co-administration of INVEGA<span class="Sup">&reg;</span> 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state C<span class="Sub">max</span> and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of INVEGA<span class="Sup">&reg;</span> should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA<span class="Sup">&reg;</span> should be re-evaluated and decreased if necessary.</p>    <p>Paliperidone is metabolized to a limited extent by CYP2D6 <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA<span class="Sup">&reg;</span> was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.</p>    <p>Co-administration of a single dose of INVEGA<span class="Sup">&reg;</span> 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the C<span class="Sub">max</span> and AUC of paliperidone. Dosage reduction for INVEGA<span class="Sup">&reg;</span> should be considered when INVEGA<span class="Sup">&reg;</span> is co-administered with valproate after clinical assessment.</p>    <p>Pharmacokinetic interaction between lithium and INVEGA<span class="Sup">&reg;</span> is unlikely.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="S8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="S8.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="section-8.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Pregnancy Category C</span>.</p>     <p>There are no adequate and well controlled studies of INVEGA<span class="Sup">&reg;</span> in pregnant women.</p>     <p>Use of first generation antipsychotic drugs during the last trimester of pregnancy has been associated with extrapyramidal symptoms in the neonate. These symptoms are usually self-limited. It is not known whether paliperidone, when taken near the end of pregnancy, will lead to similar neonatal signs and symptoms.</p>     <p>In animal reproduction studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated during the period of organogenesis with up to 8 times the maximum recommended human dose of paliperidone (on a mg/m<span class="Sup">2</span> basis).</p>     <p>In rat reproduction studies with risperidone, which is extensively converted to paliperidone in rats and humans, there were increases in pup deaths seen at oral doses which are less than the maximum recommended human dose of risperidone on a mg/m<span class="Sup">2</span> basis (see risperidone package insert).</p>    </div>    <div class="Section" data-sectioncode="34078-6">     <a name="section-8.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Non-teratogenic Effects</span> </p>     <p>Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>     <p>INVEGA<span class="Sup">&reg; </span>should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>    </div>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="S8.3"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">Paliperidone is excreted in human breast milk. The known benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="S8.4"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">Safety and effectiveness of INVEGA<span class="Sup">&reg;</span> in the treatment of schizophrenia were evaluated in 150 adolescent subjects 12–17 years of age with schizophrenia who received INVEGA<span class="Sup">&reg;</span> in the dose range of 1.5 mg to 12 mg/day in a 6-week, double-blind, placebo-controlled trial.</p>    <p>Safety and effectiveness of INVEGA<span class="Sup">&reg;</span> for the treatment of schizophrenia in patients &lt; 12 years of age have not been established. Safety and effectiveness of INVEGA<span class="Sup">&reg;</span> for the treatment of schizoaffective disorder in patients &lt; 18 years of age have not been studied.</p>    <p>In a study in which juvenile rats were treated with oral paliperidone from days 24 to 73 of age, a reversible impairment of performance in a test of learning and memory was seen, in females only, with a no-effect dose of 0.63 mg/kg/day, which produced plasma levels (AUC) of paliperidone similar to those in adolescents. No other consistent effects on neurobehavioral or reproductive development were seen up to the highest dose tested (2.5 mg/kg/day), which produced plasma levels of paliperidone 2–3 times those in adolescents.</p>    <p>Juvenile dogs were treated for 40 weeks with oral risperidone, which is extensively metabolized to paliperidone in animals and humans, at doses of 0.31, 1.25, or 5 mg/kg/day. Decreased bone length and density were seen with a no-effect dose of 0.31 mg/kg/day, which produced plasma levels (AUC) of risperidone plus paliperidone which were similar to those in children and adolescents receiving the maximum recommended human dose of risperidone. In addition, a delay in sexual maturation was seen at all doses in both males and females. The above effects showed little or no reversibility in females after a 12-week drug-free recovery period.</p>    <p>The long-term effects of INVEGA<span class="Sup">&reg;</span> on growth and sexual maturation have not been fully evaluated in children and adolescents.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="S8.5"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">The safety, tolerability, and efficacy of INVEGA<span class="Sup">&reg;</span> were evaluated in a 6-week placebo-controlled study of 114 elderly subjects with schizophrenia (65 years of age and older, of whom 21 were 75 years of age and older). In this study, subjects received flexible doses of INVEGA<span class="Sup">&reg;</span> (3 mg to 12 mg once daily). In addition, a small number of subjects 65 years of age and older were included in the 6-week placebo-controlled studies in which adult schizophrenic subjects received fixed doses of INVEGA<span class="Sup">&reg;</span> (3 mg to 15 mg once daily) <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. There were no subjects ≥ 65 years of age in the schizoaffective disorder studies.</p>    <p>Overall, of the total number of subjects in schizophrenia clinical studies of INVEGA<span class="Sup">&reg;</span> (n = 1796), including those who received INVEGA<span class="Sup">&reg;</span> or placebo, 125 (7.0%) were 65 years of age and older and 22 (1.2%) were 75 years of age and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>    <p>This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with moderate to severe renal impairment <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>, who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.6"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 Renal Impairment</h2>    <p class="First">Dosing must be individualized according to the patient's renal function status <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.7"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.7 Hepatic Impairment</h2>    <p class="First">No dosage adjustment is required in patients with mild to moderate hepatic impairment. INVEGA<span class="Sup">&reg;</span> has not been studied in patients with severe hepatic impairment.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a> <div class="Section toggle-content closed" data-sectioncode="42227-9">   <a name="S9"></a>  <a name="section-9"></a>   <p></p>    <div class="Section" data-sectioncode="34085-1">    <a name="S9.1"></a>   <a name="section-9.1"></a>    <p></p>    <h2>9.1 Controlled Substance</h2>    <p class="First">INVEGA<span class="Sup">&reg;</span> (paliperidone) is not a controlled substance.</p>   </div>   <div class="Section" data-sectioncode="34086-9">    <a name="S9.2"></a>   <a name="section-9.2"></a>    <p></p>    <h2>9.2 Abuse</h2>    <p class="First">Paliperidone has not been systematically studied in animals or humans for its potential for abuse. It is not possible to predict the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of INVEGA<span class="Sup">&reg; </span>misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).</p>   </div>   <div class="Section" data-sectioncode="34087-7">    <a name="S9.3"></a>   <a name="section-9.3"></a>    <p></p>    <h2>9.3 Dependence</h2>    <p class="First">Paliperidone has not been systematically studied in animals or humans for its potential for tolerance or physical dependence.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="S10"></a>  <a name="section-10"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S10.1"></a>   <a name="section-10.1"></a>    <p></p>    <h2>10.1 Human Experience</h2>    <p class="First">While experience with paliperidone overdose is limited, among the few cases of overdose reported in pre-marketing trials, the highest estimated ingestion of INVEGA<span class="Sup">&reg;</span> was 405 mg. Observed signs and symptoms included extrapyramidal symptoms and gait unsteadiness. Other potential signs and symptoms include those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and somnolence, tachycardia and hypotension, and QT prolongation. Torsade de pointes and ventricular fibrillation have been reported in a patient in the setting of overdose.</p>    <p>Paliperidone is the major active metabolite of risperidone. Overdose experience reported with risperidone can be found in the OVERDOSAGE section of the risperidone package insert.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S10.2"></a>   <a name="section-10.2"></a>    <p></p>    <h2>10.2 Management of Overdosage</h2>    <p class="First">There is no specific antidote to paliperidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consideration should be given to the extended-release nature of the product when assessing treatment needs and recovery. Multiple drug involvement should also be considered.</p>    <p>In case of acute overdose, establish and maintain an airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.</p>    <p>The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.</p>    <p>Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of paliperidone. Similarly the alpha-blocking properties of bretylium might be additive to those of paliperidone, resulting in problematic hypotension.</p>    <p>Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of paliperidone-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="S11"></a>  <a name="section-11"></a>   <p></p>    <p class="First">Paliperidone, the active ingredient in INVEGA<span class="Sup">&reg;</span> Extended-Release Tablets, is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. INVEGA<span class="Sup">&reg;</span> contains a racemic mixture of (+)- and (-)- paliperidone. The chemical name is (&plusmn;)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is C<span class="Sub">23</span>H<span class="Sub">27</span>FN<span class="Sub">4</span>O<span class="Sub">3</span> and its molecular weight is 426.49. The structural formula is:</p>   <div class="Figure">    <img src="image.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&name=invega%2D01%2Ejpg" alt="Chemical Structure" />  </div>   <p>Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide.</p>   <p>INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets are available in 1.5 mg (orange-brown), 3 mg (white), 6 mg (beige), and 9 mg (pink) strengths. INVEGA<span class="Sup">&reg;</span> utilizes OROS<span class="Sup">&reg;</span> osmotic drug-release technology <span class="Italics">[see <a href="#S11.1">Description (11.1)</a>]</span>.</p>   <p>Inactive ingredients are carnauba wax, cellulose acetate, hydroxyethyl cellulose, propylene glycol, polyethylene glycol, polyethylene oxides, povidone, sodium chloride, stearic acid, butylated hydroxytoluene, hypromellose, titanium dioxide, and iron oxides. The 3 mg tablets also contain lactose monohydrate and triacetin.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="S11.1"></a>   <a name="section-11.1"></a>    <p></p>    <h2>11.1 Delivery System Components and Performance</h2>    <p class="First">INVEGA<span class="Sup">&reg;</span> uses osmotic pressure to deliver paliperidone at a controlled rate. The delivery system, which resembles a capsule-shaped tablet in appearance, consists of an osmotically active trilayer core surrounded by a subcoat and semipermeable membrane. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There are two precision laser-drilled orifices on the drug-layer dome of the tablet. Each tablet strength has a different colored water-dispersible overcoat and print markings. In an aqueous environment, such as the gastrointestinal tract, the water-dispersible color overcoat erodes quickly. Water then enters the tablet through the semipermeable membrane that controls the rate at which water enters the tablet core, which, in turn, determines the rate of drug delivery. The hydrophilic polymers of the core hydrate and swell, creating a gel containing paliperidone that is then pushed out through the tablet orifices. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the stool as a tablet shell, along with insoluble core components.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="S12"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="S12.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D<span class="Sub">2</span>) and serotonin Type 2 (5HT<span class="Sub">2A</span>) receptor antagonism.</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="S12.2"></a>   <a name="section-12.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First">Paliperidone is a centrally active dopamine Type 2 (D<span class="Sub">2</span>) antagonist and with predominant serotonin Type 2 (5HT<span class="Sub">2A</span>) activity. Paliperidone is also active as an antagonist at α<span class="Sub">1</span> and α<span class="Sub">2</span> adrenergic receptors and H<span class="Sub">1</span> histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone has no affinity for cholinergic muscarinic or β<span class="Sub">1</span>- and β<span class="Sub">2</span>-adrenergic receptors. The pharmacological activity of the (+)- and (-)- paliperidone enantiomers is qualitatively and quantitatively similar <span class="Italics">in vitro.</span> </p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="S12.3"></a>   <a name="section-12.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First">Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C<span class="Sub">max</span>) approximately 24 hours after dosing. The pharmacokinetics of paliperidone following INVEGA<span class="Sup">&reg;</span> administration are dose-proportional within the available dose range. The terminal elimination half-life of paliperidone is approximately 23 hours.</p>    <p>Steady-state concentrations of paliperidone are attained within 4–5 days of dosing with INVEGA<span class="Sup">&reg;</span> in most subjects. The mean steady-state peak:trough ratio for an INVEGA<span class="Sup">&reg;</span> dose of 9 mg was 1.7 with a range of 1.2–3.1.</p>    <p>Following administration of INVEGA<span class="Sup">&reg;</span>, the (+) and (-) enantiomers of paliperidone interconvert, reaching an AUC (+) to (-) ratio of approximately 1.6 at steady state.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.3.1"></a>     <p></p>     <p class="First"> <span class="Underline">Absorption and Distribution</span> </p>     <p>The absolute oral bioavailability of paliperidone following INVEGA<span class="Sup">&reg;</span> administration is 28%.</p>     <p>Administration of a 12 mg paliperidone extended-release tablet to healthy ambulatory subjects with a standard high-fat/high-caloric meal gave mean C<span class="Sub">max</span> and AUC values of paliperidone that were increased by 60% and 54%, respectively, compared with administration under fasting conditions. Clinical trials establishing the safety and efficacy of INVEGA<span class="Sup">&reg;</span> were carried out in subjects without regard to the timing of meals. While INVEGA<span class="Sup">&reg;</span> can be taken without regard to food, the presence of food at the time of INVEGA<span class="Sup">&reg;</span> administration may increase exposure to paliperidone <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</p>     <p>Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L. The plasma protein binding of racemic paliperidone is 74%.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.3.2"></a>     <p></p>     <p class="First"> <span class="Underline">Metabolism and Elimination</span> </p>     <p>Although <span class="Italics">in vitro </span>studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, <span class="Italics">in vivo </span>results indicate that these isozymes play a limited role in the overall elimination of paliperidone <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>.</p>     <p>One week following administration of a single oral dose of 1 mg immediate-release <span class="Sup">14</span>C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the feces. Four primary metabolic pathways have been identified <span class="Italics">in vivo</span>, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.</p>     <p>Population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.3.3"></a>     <p></p>     <p class="First"> <span class="Underline">Special Populations</span> </p>     <div class="Section" data-sectioncode="42229-5">      <a name="Renal_Impairment"></a>     <a name="section-12.3.3.1"></a>      <p></p>      <p class="First"> <span class="Italics">Renal Impairment</span> </p>      <p>The dose of INVEGA<span class="Sup">&reg;</span> should be reduced in patients with moderate or severe renal impairment<span class="Italics"> [see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>. The disposition of a single dose paliperidone 3 mg extended-release tablet was studied in adult subjects with varying degrees of renal function. Elimination of paliperidone decreased with decreasing estimated creatinine clearance. Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 mL/min to &lt; 80 mL/min), 64% in moderate (CrCl = 30 mL/min to &lt; 50 mL/min), and 71% in severe (CrCl = 10 mL/min to &lt; 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUCinf) of 1.5 fold, 2.6 fold, and 4.8 fold, respectively, compared to healthy subjects. The mean terminal elimination half-life of paliperidone was 24 hours, 40 hours, and 51 hours in subjects with mild, moderate, and severe renal impairment, respectively, compared with 23 hours in subjects with normal renal function (CrCl ≥ 80 mL/min).</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.3.2"></a>      <p></p>      <p class="First"> <span class="Italics">Hepatic Impairment</span> </p>      <p>In a study in adult subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects, although total paliperidone exposure decreased because of a decrease in protein binding. Consequently, no dose adjustment is required in patients with mild or moderate hepatic impairment. INVEGA<span class="Sup">&reg;</span> has not been studied in patients with severe hepatic impairment.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.3.3"></a>      <p></p>      <p class="First"> <span class="Italics">Adolescents (12–17 years of age)</span> </p>      <p>Paliperidone systemic exposure in adolescents weighing ≥ 51 kg (≥ 112 lbs) was similar to that in adults. In adolescents weighing &lt; 51 kg (&lt; 112 lbs), a 23% higher exposure was observed; this is considered not to be clinically significant. Age did not influence the paliperidone exposure.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.3.4"></a>      <p></p>      <p class="First"> <span class="Italics">Elderly</span> </p>      <p>No dosage adjustment is recommended based on age alone. However, dose adjustment may be required because of age-related decreases in creatinine clearance <span class="Italics">[see <a href="#Renal_Impairment">Renal Impairment</a> above and <a href="#S2.1">Dosage and Administration (2.1</a>, <a href="#S2.5">2.5</a>)]</span>.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.3.5"></a>      <p></p>      <p class="First"> <span class="Italics">Race</span> </p>      <p>No dosage adjustment is recommended based on race. No differences in pharmacokinetics were observed in a pharmacokinetic study conducted in Japanese and Caucasians.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.3.6"></a>      <p></p>      <p class="First"> <span class="Italics">Gender</span> </p>      <p>No dosage adjustment is recommended based on gender. No differences in pharmacokinetics were observed in a pharmacokinetic study conducted in men and women.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.3.7"></a>      <p></p>      <p class="First"> <span class="Italics">Smoking</span> </p>      <p>No dosage adjustment is recommended based on smoking status. Based on in vitro studies utilizing human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone.</p>     </div>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="S13"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="S13.1"></a>   <a name="section-13.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Carcinogenesis </span> </p>     <p>Carcinogenicity studies of paliperidone have not been performed.</p>     <p>Carcinogenicity studies of risperidone, which is extensively converted to paliperidone in rats, mice, and humans, were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at daily doses of 0.63 mg/kg, 2.5 mg/kg, and 10 mg/kg for 18 months to mice and for 25 months to rats. A maximum tolerated dose was not achieved in male mice. There were statistically significant increases in pituitary gland adenomas, endocrine pancreas adenomas, and mammary gland adenocarcinomas. The no-effect dose for these tumors was less than or equal to the maximum recommended human dose of risperidone on a mg/m2 basis (see risperidone package insert). An increase in mammary, pituitary, and endocrine pancreas neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be mediated by prolonged dopamine D2 antagonism and hyperprolactinemia. The relevance of these tumor findings in rodents in terms of human risk is unknown <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Mutagenesis</span> </p>     <p>No evidence of genotoxic potential for paliperidone was found in the Ames reverse mutation test, the mouse lymphoma assay, or the <span class="Italics">in vivo</span> rat micronucleus test.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.1.3"></a>     <p></p>     <p class="First"> <span class="Underline">Impairment of Fertility</span> </p>     <p>In a study of fertility, the percentage of treated female rats that became pregnant was not affected at oral doses of paliperidone of up to 2.5 mg/kg/day. However, pre- and post-implantation loss was increased, and the number of live embryos was slightly decreased, at 2.5 mg/kg, a dose that also caused slight maternal toxicity. These parameters were not affected at a dose of 0.63 mg/kg, which is half of the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis.</p>     <p>The fertility of male rats was not affected at oral doses of paliperidone of up to 2.5 mg/kg/day, although sperm count and sperm viability studies were not conducted with paliperidone. In a subchronic study in Beagle dogs with risperidone, which is extensively converted to paliperidone in dogs and humans, all doses tested (0.31 mg/kg – 5.0 mg/kg) resulted in decreases in serum testosterone and in sperm motility and concentration. Serum testosterone and sperm parameters partially recovered, but remained decreased after the last observation (two months after treatment was discontinued).</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="S14"></a>  <a name="section-14"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S14.1"></a>   <a name="section-14.1"></a>    <p></p>    <h2>14.1 Schizophrenia</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-14.1.1"></a>     <p></p>     <p class="First">Adults</p>     <p>The acute efficacy of INVEGA<span class="Sup">&reg;</span> (3 mg to 15 mg once daily) was established in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in non-elderly adult subjects (mean age of 37) who met DSM-IV criteria for schizophrenia. Studies were carried out in North America, Eastern Europe, Western Europe, and Asia. The doses studied among these three trials included 3 mg/day, 6 mg/day, 9 mg/day, 12 mg/day, and 15 mg/day. Dosing was in the morning without regard to meals.</p>     <p>Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS), a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. Efficacy was also evaluated using the Personal and Social Performance (PSP) scale. The PSP is a validated clinician-rated scale that measures personal and social functioning in the domains of socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors.</p>     <p>In all 3 studies (n = 1665), INVEGA<span class="Sup">&reg;</span> was superior to placebo on the PANSS at all doses. Mean effects at all doses were fairly similar, although the higher doses in all studies were numerically superior. INVEGA<span class="Sup">&reg;</span> was also superior to placebo on the PSP in these trials.</p>     <p>An examination of population subgroups did not reveal any evidence of differential responsiveness on the basis of gender, age (there were few patients over 65), or geographic region. There were insufficient data to explore differential effects based on race.</p>     <p>In a longer-term trial, adult outpatients meeting DSM-IV criteria for schizophrenia who had clinically responded (defined as PANSS score ≤ 70 or ≤ 4 on pre-defined PANSS subscales, as well as having been on a stable fixed dose of INVEGA<span class="Sup">&reg;</span> for the last two weeks of an 8-week run-in phase) were entered into a 6-week open-label stabilization phase where they received INVEGA<span class="Sup">&reg;</span> (doses ranging from 3 mg to 15 mg once daily). After the stabilization phase, patients were randomized in a double-blind manner to either continue on INVEGA<span class="Sup">&reg;</span> at their achieved stable dose, or to placebo, until they experienced a relapse of schizophrenia symptoms. Relapse was pre-defined as significant increase in PANSS (or pre-defined PANSS subscales), hospitalization, clinically significant suicidal or homicidal ideation, or deliberate injury to self or others. An interim analysis of the data showed a significantly longer time to relapse in patients treated with INVEGA<span class="Sup">&reg;</span> compared to placebo, and the trial was stopped early because maintenance of efficacy was demonstrated.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-14.1.2"></a>     <p></p>     <p class="First">Adolescents</p>     <p>The efficacy of INVEGA<span class="Sup">&reg;</span> in adolescent subjects with schizophrenia was established in a randomized, double-blind, parallel-group, placebo-controlled, 6-week study using a fixed-dose weight-based treatment group design over the dose range of 1.5 to 12 mg/day. The study was carried out in the US, India, Romania, Russia, and Ukraine, and involved subjects 12–17 years of age meeting DSM-IV criteria for schizophrenia, with diagnosis confirmation using the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL).</p>     <p>Eligible subjects were randomly assigned to 1 of 4 treatment groups: a placebo group or INVEGA<span class="Sup">&reg;</span> Low, Medium, or High dose groups. Doses were administered based on body weight to minimize the risk of exposing lower-weight adolescents to high doses of INVEGA<span class="Sup">&reg;</span>. Subjects weighing between 29 kg and less than 51 kg at the baseline visit were randomly assigned to receive placebo or 1.5 mg (Low dose), 3 mg (Medium dose), or 6 mg (High dose) of INVEGA<span class="Sup">&reg;</span> daily, and subjects weighing at least 51 kg at the baseline visit were randomly assigned to receive placebo or 1.5 mg (Low dose), 6 mg (Medium dose), or 12 mg (High dose) of INVEGA<span class="Sup">&reg;</span> daily. Dosing was in the morning without regard to meals.</p>     <p>Efficacy was evaluated using PANSS. Overall, this study demonstrated the efficacy of INVEGA<span class="Sup">&reg;</span> in adolescents with schizophrenia in the dose range of 3 to 12 mg/day. Doses within this broad range were shown to be effective, however, there was no clear enhancement to efficacy at the higher doses, i.e., 6 mg for subjects weighing less than 51 kg and 12 mg for subjects weighing 51 kg or greater. Although paliperidone was adequately tolerated within the dose range of 3 to 12 mg/day, adverse events were dose related.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S14.2"></a>   <a name="section-14.2"></a>    <p></p>    <h2>14.2 Schizoaffective Disorder</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-14.2.1"></a>     <p></p>     <p class="First">Adults</p>     <p>The acute efficacy of INVEGA<span class="Sup">&reg;</span> (3 mg to 12 mg once daily) in the treatment of schizoaffective disorder was established in two placebo-controlled, 6-week trials in non-elderly adult subjects. Enrolled subjects 1) met DSM-IV criteria for schizoaffective disorder, as confirmed by the Structured Clinical Interview for DSM-IV Disorders, 2) had a Positive and Negative Syndrome Scale (PANSS) total score of at least 60, and 3) had prominent mood symptoms as confirmed by a score of at least 16 on the Young Mania Rating Scale and/or Hamilton Rating Scale for Depression. The population included subjects with schizoaffective bipolar and depressive types. In one of these trials, efficacy was assessed in 211 subjects who received flexible doses of INVEGA<span class="Sup">&reg;</span> (3–12 mg once daily). In the other study, efficacy was assessed in 203 subjects who were assigned to one of two dose levels of INVEGA<span class="Sup">&reg;</span>: 6 mg with the option to reduce to 3 mg (n = 105) or 12 mg with the option to reduce to 9 mg (n = 98) once daily. Both studies included subjects who received INVEGA<span class="Sup">&reg;</span> either as monotherapy [no mood stabilizers and/or antidepressants (55%)] or as an adjunct to mood stabilizers and/or antidepressants (45%). The most commonly used mood stabilizers were valproate and lithium. The most commonly used antidepressants were SSRIs and SNRIs. INVEGA<span class="Sup">&reg;</span> was dosed in the morning without regard to meals. Studies were carried out in the United States, Eastern Europe, Russia, and Asia.</p>     <p>Efficacy was evaluated using the PANSS, a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. As secondary outcomes, mood symptoms were evaluated using the Hamilton Depression Rating Scale (HAM-D-21) and the Young Mania Rating Scale (YMRS).</p>     <p>The INVEGA<span class="Sup">&reg;</span> group in the flexible-dose study (dosed between 3 and 12 mg/day, mean modal dose of 8.6 mg/day) and the higher dose group of INVEGA<span class="Sup">&reg;</span> in the 2 dose-level study (12 mg/day with option to reduce to 9 mg/day) were each superior to placebo in the PANSS. Numerical improvements in mood symptoms were also observed, as measured by the HAM-D-21 and YMRS. In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), INVEGA<span class="Sup">&reg;</span> was not significantly different from placebo as measured by the PANSS.</p>     <p>Taking the results of both studies together, INVEGA<span class="Sup">&reg;</span> improved the symptoms of schizoaffective disorder at endpoint relative to placebo when administered either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. An examination of population subgroups did not reveal any evidence of differential responsiveness on the basis of gender, age, or geographic region. There were insufficient data to explore differential effects based on race.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="S16"></a>  <a name="section-15"></a>   <p></p>    <p class="First">INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets are available in the following strengths and packages. All tablets are capsule-shaped.</p>   <p>1.5 mg tablets are orange-brown and imprinted with &quot;PAL 1.5&quot;, and are available in bottles of 30 (NDC 50458-554-01).</p>   <p>3 mg tablets are white and imprinted with &quot;PAL 3&quot;, and are available in bottles of 30 (NDC 50458-550-01) and hospital unit dose packs of 100 (NDC 50458-550-10).</p>   <p>6 mg tablets are beige and imprinted with &quot;PAL 6&quot;, and are available in bottles of 30 (NDC 50458-551-01) and hospital unit dose packs of 100 (NDC 50458-551-10).</p>   <p>9 mg tablets are pink and imprinted with &quot;PAL 9&quot;, and are available in bottles of 30 (NDC 50458-552-01) and hospital unit dose packs of 100 (NDC 50458-552-10).</p>   <div class="Section" data-sectioncode="44425-7">    <a name="section-15.1"></a>    <p></p>    <p class="First"> <span class="Bold">Storage and Handling</span> </p>    <p>Store up to 25&deg;C (77&deg;F); excursions permitted to 15 – 30&deg;C (59 – 86&deg;F) [see USP Controlled Room Temperature]. Protect from moisture.</p>    <p>Keep out of reach of children.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="S17"></a>  <a name="section-16"></a>   <p></p>    <p class="First">Physicians are advised to discuss the following issues with patients for whom they prescribe INVEGA<span class="Sup">&reg;</span>.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.1"></a>   <a name="section-16.1"></a>    <p></p>    <h2>17.1 Orthostatic Hypotension</h2>    <p class="First">Patients should be advised that there is risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.2"></a>   <a name="section-16.2"></a>    <p></p>    <h2>17.2 Interference with Cognitive and Motor Performance</h2>    <p class="First">As INVEGA<span class="Sup">&reg;</span> has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that INVEGA<span class="Sup">&reg;</span> therapy does not affect them adversely <span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.3"></a>   <a name="section-16.3"></a>    <p></p>    <h2>17.3 Pregnancy</h2>    <p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with INVEGA<span class="Sup">&reg;</span><span class="Italics"> [see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.4"></a>   <a name="section-16.4"></a>    <p></p>    <h2>17.4 Nursing</h2>    <p class="First">Caution should be exercised when INVEGA<span class="Sup">&reg;</span> is administered to a nursing woman. The known benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone. <span class="Italics">[See <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.5"></a>   <a name="section-16.5"></a>    <p></p>    <h2>17.5 Concomitant Medication</h2>    <p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.6"></a>   <a name="section-16.6"></a>    <p></p>    <h2>17.6 Alcohol</h2>    <p class="First">Patients should be advised to avoid alcohol while taking INVEGA<span class="Sup">&reg; </span><span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.7"></a>   <a name="section-16.7"></a>    <p></p>    <h2>17.7 Heat Exposure and Dehydration</h2>    <p class="First">Patients should be advised regarding appropriate care in avoiding overheating and dehydration <span class="Italics">[see <a href="#S5.17">Warnings and Precautions (5.17)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.8"></a>   <a name="section-16.8"></a>    <p></p>    <h2>17.8 Administration</h2>    <p class="First">Patients should be informed that INVEGA<span class="Sup">&reg;</span> should be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice something that looks like a tablet in their stool <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="section-17"></a>   <p></p>   <p class="First">INVEGA<span class="Sup">&reg;</span> (paliperidone) Extended-Release Tablets</p>   <p>Product of Ireland</p>   <p>Manufactured by:<br /> ALZA Corporation<br /> Vacaville, CA 95688<br /> OR<br /> Janssen Cilag Manufacturing, LLC<br /> Gurabo, Puerto Rico 00778</p>   <p>Manufactured for:<br /> Janssen Pharmaceuticals, Inc. <br />Titusville, NJ 08560</p>   <p>OROS is a registered trademark of ALZA Corporation</p>   <p>&copy;Janssen Pharmaceuticals, Inc. 2007</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-18"></a>   <p></p>   <p class="First"> <span class="Bold">PRINCIPAL DISPLAY PANEL - 1.5 mg Bottle Label</span> </p>   <p>NDC 50458-554-01</p>   <p> <span class="Bold">INVEGA<span class="Sup">&reg;</span> <br />PALIPERIDONE<br />Extended-Release Tablets</span> </p>   <p> <span class="Bold">1.5 mg</span> </p>   <p> <span class="Bold">Tablets should be swallowed whole. <br />Do not divide, crush, or chew.</span> <br />Invega should be taken once daily.</p>   <p>30 Tablets</p>   <p>Janssen</p>   <div class="Figure">    <img src="image.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&name=invega%2D02%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 1.5 mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-19"></a>   <p></p>   <p class="First"> <span class="Bold">PRINCIPAL DISPLAY PANEL - 3 mg Bottle Label</span> </p>   <p>NDC 50458-550-01</p>   <p> <span class="Bold">INVEGA<span class="Sup">&reg;</span> <br />PALIPERIDONE<br />Extended-Release Tablets</span> </p>   <p> <span class="Bold">3 mg</span> </p>   <p> <span class="Bold">Tablets should be swallowed whole. <br />Do not divide, crush, or chew.</span> <br />Invega should be taken once daily.</p>   <p>30 Tablets</p>   <p>Janssen</p>   <div class="Figure">    <img src="image.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&name=invega%2D03%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 3 mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-20"></a>   <p></p>   <p class="First"> <span class="Bold">PRINCIPAL DISPLAY PANEL - 6 mg Bottle Label</span> </p>   <p>NDC 50458-551-01</p>   <p> <span class="Bold">INVEGA<span class="Sup">&reg;</span> <br />PALIPERIDONE<br />Extended-Release Tablets</span> </p>   <p> <span class="Bold">6 mg</span> </p>   <p> <span class="Bold">Tablets should be swallowed whole. <br />Do not divide, crush, or chew.</span> <br />Invega should be taken once daily.</p>   <p>30 Tablets</p>   <p>Janssen</p>   <div class="Figure">    <img src="image.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&name=invega%2D04%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 6 mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-21"></a>   <p></p>   <p class="First"> <span class="Bold">PRINCIPAL DISPLAY PANEL - 9 mg Bottle Label</span> </p>   <p>NDC 50458-552-01</p>   <p> <span class="Bold">INVEGA<span class="Sup">&reg;</span> <br />PALIPERIDONE<br />Extended-Release Tablets</span> </p>   <p> <span class="Bold">9 mg</span> </p>   <p> <span class="Bold">Tablets should be swallowed whole. <br />Do not divide, crush, or chew.</span> <br />Invega should be taken once daily.</p>   <p>30 Tablets</p>   <p>Janssen</p>   <div class="Figure">    <img src="image.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&name=invega%2D05%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 9 mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>INVEGA&nbsp; </strong> <br /> <span class="contentTableReg">paliperidone tablet, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-550</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>paliperidone</strong> (UNII: 838F01T721) (paliperidone - UNII:838F01T721)</td>          <td class="formItem">paliperidone</td>          <td class="formItem">3&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carnauba wax</strong> (UNII: R12CBM0EIZ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose acetate</strong> (UNII: 3J2P07GVB6)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>propylene glycol</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>povidones</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium chloride</strong> (UNII: 451W47IQ8X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>stearic acid</strong> (UNII: 4ELV7Z65AP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>butylated hydroxytoluene</strong> (UNII: 1P9D0Z171K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferrosoferric oxide</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>triacetin</strong> (UNII: XHX3C3X673)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">WHITE</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (capsule shaped)</td>          <td class="formLabel">Size</td>          <td class="formItem">11mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">PAL;3</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-550-01</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-550-10</td>          <td class="formItem">10 in 1 BOX, UNIT-DOSE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:50458-550-98</td>          <td class="formItem">7 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021999</td>          <td class="formItem">12/19/2006</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>INVEGA&nbsp; </strong> <br /> <span class="contentTableReg">paliperidone tablet, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-551</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>paliperidone</strong> (UNII: 838F01T721) (paliperidone - UNII:838F01T721)</td>          <td class="formItem">paliperidone</td>          <td class="formItem">6&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carnauba wax</strong> (UNII: R12CBM0EIZ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose acetate</strong> (UNII: 3J2P07GVB6)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>propylene glycol</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>povidones</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium chloride</strong> (UNII: 451W47IQ8X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>stearic acid</strong> (UNII: 4ELV7Z65AP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>butylated hydroxytoluene</strong> (UNII: 1P9D0Z171K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferrosoferric oxide</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">BROWN (beige)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (capsule shaped)</td>          <td class="formLabel">Size</td>          <td class="formItem">11mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">PAL;6</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-551-01</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-551-10</td>          <td class="formItem">10 in 1 BOX, UNIT-DOSE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:50458-551-98</td>          <td class="formItem">7 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021999</td>          <td class="formItem">12/19/2006</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>INVEGA&nbsp; </strong> <br /> <span class="contentTableReg">paliperidone tablet, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-552</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>paliperidone</strong> (UNII: 838F01T721) (paliperidone - UNII:838F01T721)</td>          <td class="formItem">paliperidone</td>          <td class="formItem">9&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carnauba wax</strong> (UNII: R12CBM0EIZ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose acetate</strong> (UNII: 3J2P07GVB6)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>propylene glycol</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>povidones</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium chloride</strong> (UNII: 451W47IQ8X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>stearic acid</strong> (UNII: 4ELV7Z65AP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>butylated hydroxytoluene</strong> (UNII: 1P9D0Z171K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferrosoferric oxide</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">PINK</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (capsule shaped)</td>          <td class="formLabel">Size</td>          <td class="formItem">11mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">PAL;9</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-552-01</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-552-10</td>          <td class="formItem">10 in 1 BOX, UNIT-DOSE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:50458-552-98</td>          <td class="formItem">7 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021999</td>          <td class="formItem">12/19/2006</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>INVEGA&nbsp; </strong> <br /> <span class="contentTableReg">paliperidone tablet, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-554</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>paliperidone</strong> (UNII: 838F01T721) (paliperidone - UNII:838F01T721)</td>          <td class="formItem">paliperidone</td>          <td class="formItem">1.5&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carnauba wax</strong> (UNII: R12CBM0EIZ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose acetate</strong> (UNII: 3J2P07GVB6)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>propylene glycol</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>povidones</strong> (UNII: FZ989GH94E)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium chloride</strong> (UNII: 451W47IQ8X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>stearic acid</strong> (UNII: 4ELV7Z65AP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>butylated hydroxytoluene</strong> (UNII: 1P9D0Z171K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferrosoferric oxide</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">ORANGE (orange brown)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (capsule shaped)</td>          <td class="formLabel">Size</td>          <td class="formItem">5mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">PAL;1;5</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-554-01</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-554-10</td>          <td class="formItem">10 in 1 BOX, UNIT-DOSE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:50458-554-98</td>          <td class="formItem">7 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021999</td>          <td class="formItem">09/10/2009</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Janssen Pharmaceuticals, Inc. (063137772) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Janssen Cilag Manufacturing, LLC</td>      <td class="formItem"></td>      <td class="formItem">963971374</td>      <td class="formItem">MANUFACTURE(50458-550, 50458-551, 50458-552, 50458-554)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Alza Corporation</td>      <td class="formItem"></td>      <td class="formItem">175417641</td>      <td class="formItem">MANUFACTURE(50458-554)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Janssen Pharmaceutical</td>      <td class="formItem"></td>      <td class="formItem">985421372</td>      <td class="formItem">API MANUFACTURE(50458-550, 50458-551, 50458-552, 50458-554)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22paliperidone%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=paliperidone" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=paliperidone" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=paliperidone&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                                   <h3 class="long-title">INVEGA- paliperidone tablet, extended release <br></h3>            <h4>Number of versions: 11</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>May 6, 2014</td>                        <td>							                                17                             							(current)                         </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=138868">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 13, 2014</td>                        <td>							                                16                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=129014">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 13, 2011</td>                        <td>							                                15                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=63073">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 21, 2011</td>                        <td>							                                14                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=52646">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 28, 2011</td>                        <td>							                                13                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=49812">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 22, 2010</td>                        <td>							                                12                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=44667">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 2, 2010</td>                        <td>							                                11                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=15922">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 4, 2009</td>                        <td>							                                8                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=12003">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 5, 2009</td>                        <td>							                                6                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=9753">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 12, 2008</td>                        <td>							                                5                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=9608">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 8, 2008</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=6864">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">INVEGA- paliperidone tablet, extended release <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                                       			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672567">672567</a></td>                              <td>paliperidone 3 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672567">672567</a></td>                              <td>24 HR paliperidone 3 MG Extended Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672567">672567</a></td>                              <td>paliperidone 3 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672569">672569</a></td>                              <td>paliperidone 6 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672569">672569</a></td>                              <td>24 HR paliperidone 6 MG Extended Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672569">672569</a></td>                              <td>paliperidone 6 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672571">672571</a></td>                              <td>paliperidone 9 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672571">672571</a></td>                              <td>24 HR paliperidone 9 MG Extended Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=672571">672571</a></td>                              <td>paliperidone 9 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686441">686441</a></td>                              <td>INVEGA 3 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686441">686441</a></td>                              <td>24 HR paliperidone 3 MG Extended Release Oral Tablet [Invega]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686441">686441</a></td>                              <td>24 HR Invega 3 MG Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686441">686441</a></td>                              <td>Invega 3 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>14</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686443">686443</a></td>                              <td>INVEGA 6 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>15</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686443">686443</a></td>                              <td>24 HR paliperidone 6 MG Extended Release Oral Tablet [Invega]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>16</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686443">686443</a></td>                              <td>24 HR Invega 6 MG Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>17</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686443">686443</a></td>                              <td>Invega 6 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>18</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686445">686445</a></td>                              <td>INVEGA 9 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>19</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686445">686445</a></td>                              <td>24 HR paliperidone 9 MG Extended Release Oral Tablet [Invega]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>20</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686445">686445</a></td>                              <td>24 HR Invega 9 MG Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>21</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=686445">686445</a></td>                              <td>Invega 9 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>22</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=866103">866103</a></td>                              <td>paliperidone 1.5 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>23</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=866103">866103</a></td>                              <td>24 HR paliperidone 1.5 MG Extended Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>24</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=866103">866103</a></td>                              <td>paliperidone 1.5 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>25</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=866105">866105</a></td>                              <td>INVEGA 1.5 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>26</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=866105">866105</a></td>                              <td>24 HR paliperidone 1.5 MG Extended Release Oral Tablet [Invega]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>27</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=866105">866105</a></td>                              <td>Invega 1.5 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">INVEGA- paliperidone tablet, extended release <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                    <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>            <li><a href="dailymed/help.cfm">Help</a></li>                    </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AINVEGA%2D%20Paliperidone%20Tablet%2C%20Extended%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D7b8e5b26%2Db9e4%2D4704%2D921b%2D3c3c0d159916%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><script> var ignore_onbeforeunload = false; $("a").on('click',function(){    if(ignore_onbeforeunload){        ignore_onbeforeunload = false;    }})$("a[href^='mailto'], a[href$='zip']").on('click',function(){    ignore_onbeforeunload = true;});$(window).on('beforeunload', function(){    if (!ignore_onbeforeunload){        // Only run the loading icon if changing the page takes longer than 200ms        setTimeout(function(){            // Fade in the grey screen            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"></div>').fadeIn('fast'));            var opts = {                  lines: 12 // The number of lines to draw                , length: 14 // The length of each line                , width: 5 // The line thickness                , radius: 14 // The radius of the inner circle                , scale: 1 // Scales overall size of the spinner                , corners: 1 // Corner roundness (0..1)                , color: '#fff'                 , opacity: 0.25 // Opacity of the lines                , rotate: 0 // The rotation offset                , direction: 1 // 1: clockwise, -1: counterclockwise                , speed: 1 // Rounds per second                , trail: 60 // Afterglow percentage                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS                , zIndex: 2e9 // The z-index (defaults to 2000000000)                , className: 'spinner' // The CSS class to assign to the spinner                , top: '50%' // Top position relative to parent                , left: '50%' // Left position relative to parent                , shadow: false // Whether to render a shadow                , hwaccel: false // Whether to use hardware acceleration                , position: 'absolute' // Element positioning                }            var spinner = new Spinner(opts).spin();            $('.loading-wrapper').append(spinner.el);        }, 200);    }    //ignore_onbeforeunload = false;});</script><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    